[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 698
1. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz i Altaba A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med; 2009 Sep;1(6-7):338-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion.
  • Human colon cancers often start as benign adenomas through loss of APC, leading to enhanced beta CATENIN (beta CAT)/TCF function.
  • We find that epithelial cells of human colon carcinomas (CCs) and their stem cells of all stages harbour an active HH-GLI pathway.
  • We show that the growth of CC xenografts, their recurrence and metastases require HH-GLI function, which induces a robust epithelial-to-mesenchymal transition (EMT).
  • Moreover, using a novel tumour cell competition assay we show that the self-renewal of CC stem cells in vivo relies on HH-GLI activity.
  • Targeting HH-GLI1, directly or indirectly, is thus predicted to decrease tumour bulk and eradicate CC stem cells and metastases.
  • [MeSH-major] Carcinoma / metabolism. Colonic Neoplasms / metabolism. Epithelial Cells / metabolism. Hedgehog Proteins / metabolism. Neoplastic Stem Cells / cytology. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Signal Transduction / drug effects. Veratrum Alkaloids / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):117-23 [16473672.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):369-79 [19280222.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Development. 2001 Dec;128(24):5201-12 [11748155.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Development. 2004 Jan;131(2):337-45 [14681189.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):277-82 [14770182.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] J Pathol. 2004 Aug;203(4):909-17 [15258993.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):257-75 [15328011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Teratology. 1970 May;3(2):175-80 [4986632.001]
  • [Cites] Lipids. 1978 Oct;13(10):708-15 [723484.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Development. 1999 Jun;126(14):3205-16 [10375510.001]
  • [Cites] Development. 2005 Jan;132(2):279-89 [15590741.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2187-2194.e1 [19324043.001]
  • [Cites] Surgery. 2006 May;139(5):665-70 [16701100.001]
  • [Cites] Gut. 2006 Jul;55(7):991-9 [16299030.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1238-9 [17287906.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] World J Gastroenterol. 2007 Mar 21;13(11):1659-65 [17461467.001]
  • [Cites] Trends Cell Biol. 2007 Sep;17(9):438-47 [17845852.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2622-7 [17683069.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):603-7 [19092805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4254-9 [19246386.001]
  • [Cites] EMBO J. 2009 Mar 18;28(6):663-76 [19214186.001]
  • [CommentIn] EMBO Mol Med. 2010 Oct;2(10):385-6; author reply 386-7 [20721989.001]
  • [CommentIn] EMBO Mol Med. 2009 Sep;1(6-7):300-2 [20049733.001]
  • (PMID = 20049737.001).
  • [ISSN] 1757-4684
  • [Journal-full-title] EMBO molecular medicine
  • [ISO-abbreviation] EMBO Mol Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ PMC3378144
  •  go-up   go-down


2. Antic T, Kapur U, Vigneswaran WT, Oshima K: Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance. Arch Pathol Lab Med; 2005 Oct;129(10):1334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance.
  • Inflammatory sarcomatoid carcinoma is an aggressive tumor with an unusually benign appearance.
  • We report the case of a 65-year-old man with a history of inoperable poorly differentiated carcinoma of the right lung, for which he had received chemoradiotherapy.
  • Results of immunoperoxidase studies, however, showed that the nodule contained neoplastic cells with an epithelial phenotype that were invading the pulmonary vessels.
  • In contrast to sarcomatoid carcinomas, this case highlights the deceptively benign appearance of inflammatory sarcomatoid carcinoma.
  • This leads us to concur with the recommendation to exercise caution when attempting the diagnosis of apparently benign lesions on intraoperative frozen section in patients with high clinical suspicion of malignancy.
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Bronchiolitis Obliterans / diagnosis. Diagnosis, Differential. Humans. Lymphomatoid Granulomatosis. Male. Neoplasm Invasiveness. Neoplasms, Second Primary. Pneumonia / diagnosis. Sarcoma / diagnosis. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196527.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


3. Katori H, Nozawa A, Tsukuda M: Histopathological parameters of recurrence and malignant transformation in sinonasal inverted papilloma. Acta Otolaryngol; 2006 Feb;126(2):214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, the parameters hyperkeratosis, squamous epithelial hyperplasia and high mitotic index were negative prognostic indicators.
  • MATERIAL AND METHODS: We analyzed the histopathological characteristics of 39 cases of IP using the following parameters: site of origin of tumor; presence of bone invasion; presence of inflammatory polyp; ratio of endophytic to exophytic lesions; ratio of neoplastic epithelium to stroma; presence of hyperkeratosis; presence of squamous epithelial hyperplasia; mitotic index; number of mucin globules; and number of eosinophils.
  • RESULTS: Malignancy was related to the presence of bone invasion (p=0.039), the absence of inflammatory polyp (p=0.033), increase in the ratio neoplastic epithelium:stroma (p=0.037), increase in hyperkeratosis (p=0.030), the presence of squamous epithelial hyperplasia (p=0.044), increase in the mitotic index (p=0.029) and a decrease in the number of eosinophils (p=0.037).
  • Multiple recurrences (without malignancy) were related to frontal sinus origin (p=0.042), increase in hyperkeratosis (p=0.041), the presence of squamous epithelial hyperplasia (p=0.044) and increase in the mitotic index (p=0.031).
  • Clinically benign behavior was related to the presence of inflammatory polyp (p=0.010) and the absence of hyperkeratosis (p=0.008).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / pathology. Papilloma, Inverted / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Eosinophils. Epithelium. Female. Humans. Hyperplasia. Male. Middle Aged. Mitotic Index. Mucins. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428203.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


Advertisement
4. Giudice C, Marco R, Mirko R, Luca M, Giorgio C: Zygomatic gland adenoma in a dog: histochemical and immunohistochemical evaluation. Vet Ophthalmol; 2005 Jan-Feb;8(1):13-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Orbital epithelial tumors in dogs are rare and most frequently malignant.
  • Distinguishing their origin from the lacrimal or zygomatic gland is often challenging and is based mostly on tumor location.
  • Histologically, the neoplasm was characterized by nests and cords of epithelial cells mostly forming small glandular structures.
  • The origin of the tumor from the zygomatic gland was determined by histochemical characteristics (alcian blue pH 1 positive staining) of a small remnant of normal gland included within the tumor capsule.
  • The benign nature of our finding was confirmed by follow-up information: 2 years after complete surgical removal of the mass no tumor recurrence or metastases was recorded.
  • [MeSH-major] Adenoma / veterinary. Dog Diseases / diagnosis. Lacrimal Apparatus. Orbital Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644095.001).
  • [ISSN] 1463-5216
  • [Journal-full-title] Veterinary ophthalmology
  • [ISO-abbreviation] Vet Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


6. Cavaco BM, Batista PF, Sobrinho LG, Leite V: Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab; 2008 Nov;93(11):4426-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis.
  • CONTEXT: Familial nonmedullary thyroid carcinoma (FNMTC) accounts for approximately 5% of all thyroid tumors.
  • OBJECTIVE: Our objective was to map the gene predisposing to familial thyroid epithelial neoplasia in a large Portuguese family.
  • METHODS AND RESULTS: The clinical screening of a Portuguese family identified 11 members affected with benign thyroid lesions and five affected with thyroid carcinomas.
  • To map the gene predisposing to thyroid epithelial neoplasia in this family, a genome-wide linkage analysis was conducted, using DNA samples from 17 family members and high-density single-nucleotide polymorphism arrays.
  • Allelic losses in the 8p23.1-p22 region were absent in seven thyroid tumors from family members, suggesting that the inactivation of a putative tumor suppressor gene may have occurred through other mechanisms.
  • CONCLUSIONS: Our results present evidence for the existence of a novel familial thyroid epithelial neoplasia susceptibility locus on chromosome 8p23.1-p22, providing the basis for the identification of a gene for this disease.
  • [MeSH-minor] DNA, Neoplasm / genetics. Family. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Genome, Human. Humans. Male. Microsatellite Repeats / genetics. Pedigree. Portugal. Thyroid Diseases / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765515.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


7. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • Histologically, MMT showed a biphasic differentiation of mesenchymal and epithelial components.
  • MMT were classified according to whether these elements were benign or malignant.
  • Recurrent tumors were almost always confined to the original site.
  • CONCLUSIONS: Uterine MMT tumors according to WHO diagnostic criteria are not rare.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Comunoğlu N, Comunoğlu C, Başsüllü N, Somunkiran A, Calay Z: Müllerian adenosarcoma with sarcomatous overgrowth of the cervix: unusual large polypoid mass. Ups J Med Sci; 2007;112(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Müllerian adenosarcoma (MS) is a rare neoplasm of uterine cervix composed of benign epithelial and malignant stromal components.
  • In this report we present a MASO case, derived from uterine cervix of a 60 year-old-female patient presenting as a cervical polypoid mass, to our knowledge the second case of the English literature.
  • In spite of sarcomatous overgrowth, high mitotic activity and huge tumor size of 12,5 cms, it displayed no myometrial invasion, vascular invasion and heterologous elements.
  • [MeSH-major] Adenosarcoma / diagnosis. Mixed Tumor, Mullerian / diagnosis. Uterine Cervical Neoplasms / diagnosis


9. Nga ME, Lim KH, Tan EY, Chan P, Tan SY, Walford N: Malignant adenomyoepithelial tumor of the breast: multi-immunolabeling technique and detailed immunophenotypic study. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):100-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant adenomyoepithelial tumor of the breast: multi-immunolabeling technique and detailed immunophenotypic study.
  • A majority of these rare lesions behave in a benign fashion.
  • Malignancy is rare, and preferentially involves the epithelial component.
  • Malignancy in both epithelial and myoepithelial components is even rarer.
  • We report such a case, employing the use of a range of cytokeratins and myoepithelial markers to delineate the extent of each component.
  • In addition, we apply the relatively novel technique of multi-immunolabeling combined with Adobe Photoshop imaging to highlight the different components of the neoplasm on the same tissue section.
  • These ancillary tests can provide much needed information about the contribution of epithelial or myoepithelial components to malignant tumors, hence providing the gateway to further study into their histogenesis and natural history.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091311.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 68238-35-7 / Keratins
  •  go-up   go-down


10. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • Glucose is transported into the cell via facilitative glucose transporters, which are known to be members of a supergene family.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • Seven of 14 borderline tumors demonstrated P-LAP immunoreactivity, while 5 of 14 borderline tumors demonstrated GLUT4 immunoreactivity.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


11. Kabasawa Y, Nagumo K, Takeda Y, Kawashima N, Okada N, Omura K, Yamaguchi A, Katsube K: Amelogenin positive cells scattered in the interstitial component of odontogenic fibromas. J Clin Pathol; 2008 Jul;61(7):851-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Odontogenic tumours are often biphasic, consisting of epithelial and interstitial components, with an origin that is not well understood.
  • Odontogenic fibromas are rich in mesenchymal component, but also have many epithelial nests.
  • AIMS: To investigate the origin of this tumour by immunohistochemistry.
  • METHODS: The expression of several odontogenic and epithelial markers, including amelogenin, was investigated by immunofluorescent studies.
  • RESULTS: Immunohistochemical analysis showed that epithelial nests exhibited E-cadherin expression, but not amelogenin.
  • Amelogenin positive cells were scattered in the fibrous tissue, which did not exhibit epithelial marker expression except for epithelial membrane antigen.
  • In one case that had received a test biopsy before whole resection of tumour, amelogenin positive cells were distributed in the regenerating mucosal epithelium or subepithelial tissue.
  • CONCLUSIONS: Results indicate that amelogenin positive cells of odontogenic fibromas have an epithelial origin and may have the potential for epithelial mesenchymal transition, which has not to date been investigated in benign tumours.
  • [MeSH-major] Amelogenin / metabolism. Biomarkers, Tumor / metabolism. Odontogenic Tumors / metabolism
  • [MeSH-minor] Adult. Cadherins / metabolism. Female. Humans. Male. Mandibular Neoplasms / metabolism. Mandibular Neoplasms / pathology. Maxillary Neoplasms / metabolism. Maxillary Neoplasms / pathology. Middle Aged. Neoplasm Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344235.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amelogenin; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Shimanovich I, Krahl D, Rose C: Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol; 2010 Feb;62(2):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors.
  • BACKGROUND: Trichoadenoma is a rare benign follicular tumor first described by Nikolowski 50 years ago.
  • Both trichoadenoma and desmoplastic trichoepithelioma are composed of cords of epithelial cells and cornifying cysts embedded in sclerotic stroma.
  • In trichoadenoma the cystic component predominates, while desmoplastic trichoepithelioma is a mostly solid neoplasm.
  • OBJECTIVE: The aim of this study was to investigate whether the morphologic overlap between trichoadenoma and desmoplastic trichoepithelioma translates into a similar immunohistochemical profile.
  • LIMITATIONS: This study is limited by the moderate number of these rare tumors available for immunohistochemical analysis.
  • Trichoadenoma is a distinct follicular tumor related but not identical to desmoplastic trichoepithelioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratin-20 / metabolism. Male. Merkel Cells / pathology. Middle Aged. Neoplasms, Fibroepithelial / pathology. Receptors, Androgen / metabolism. Skin / chemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115950.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Receptors, Androgen; 0 / human epithelial antigen-125
  •  go-up   go-down


13. Bhadani PP, Sen R, Bhadani UK, Karki S, Agarwal S: Is fine needle aspiration cytology (FNAC) useful in skin adnexal masses? A study on 5 cases of pilomatixoma. Indian J Pathol Microbiol; 2007 Apr;50(2):411-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Superficial cutaneous/subcutaneous nodules, caused by a variety of inflammatory, benign and malignant pathology of diverse origin, are tempting lesion for fine needle aspiration cytology (FNAC).
  • Amongst these, adnexal tumor show considerable overlap, both in clinical manifestation as well as in histopathology.
  • PMX was diagnosed on FNAC in 3 cases on finding groups of basaloid cells, ghost epithelial cells, pink fibrillary material and calcium deposits.
  • Other cases were diagnosed as epidermal inclusion cyst with the differential diagnosis of well differentiated squamous cell carcinoma and skin appendageal tumor of undetermined origin in one case each.
  • In all the cases, FNAC established epithelial nature of the lesion, excluding clinically mimicking inflammatory/neoplastic lesions of other origin.
  • FNAC should be followed by excision biopsy to accurately type the epithelial neoplasm.
  • [MeSH-major] Hair Diseases / diagnosis. Pilomatrixoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883095.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Han HS, Min SK, Lee HK, Kim SW, Park YH: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm. Surg Endosc; 2005 Oct;19(10):1367-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels for benign pancreas neoplasm.
  • BACKGROUND: Laparoscopic distal pancreatectomy to conserve the spleen is a beneficial operation for patients with benign and borderline malignancy in the pancreas.
  • METHODS: From May 2000 to July 2003, five laparoscopic distal pancreatectomies with preservation of the spleen and splenic vessels were performed for benign pancreas neoplasm at Ewha Womans University Mokdong Hospital in Seoul, Korea.
  • RESULTS: The postoperative pathologic diagnoses were two serous cystadenomas, two mucinous cystadenomas, and one solid and papillary epithelial tumor.
  • The tumors ranged in size from 1.5 to 7 cm.
  • CONCLUSION: Laparoscopic distal pancreatectomy with preservation of the spleen and splenic vessels is a relatively safe and feasible option for the management of benign tumor or borderline malignancy in the distal pancreas.

  • Genetic Alliance. consumer health - Spleen neoplasm.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 1999 Aug;9(4):290-3 [10871180.001]
  • [Cites] Surgery. 1996 Dec;120(6):1051-4 [8957494.001]
  • [Cites] Surg Endosc. 2004 Mar;18(3):402-6 [14735345.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1999;6(2):154-64 [10398903.001]
  • [Cites] Arch Surg. 1988 May;123(5):550-3 [3358679.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1358-61 [11984672.001]
  • [Cites] Surg Endosc. 1999 Jan;13(1):26-9 [9869683.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):996-1003 [12163971.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):217-8 [11961650.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):164-8 [11822953.001]
  • [Cites] J Am Coll Surg. 2001 Sep;193(3):281-7 [11548798.001]
  • [Cites] Acta Chir Hung. 1997;36(1-4):359-61 [9408401.001]
  • [Cites] Surg Endosc. 2001 Jul;15(7):759 [11591991.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):149-58 [12170019.001]
  • [Cites] Am J Surg. 1996 Oct;172(4):320-3 [8873521.001]
  • [Cites] Surg Endosc. 1994 Jan;8(1):57-60; discussion 60-1 [8153866.001]
  • (PMID = 16193376.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


15. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of mammaglobin B in epithelial ovarian carcinomas.
  • In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC).
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • In contrast, normal human ovarian surface epithelium (HOSE) expressed negligible levels of Mammaglobin B mRNA (EOC versus HOSE, p<0.01).
  • Although Mammaglobin B gene expression levels were higher in endometrioid, mucinous and undifferentiated tumors when compared to serous papillary tumors, clear cell tumors and those with mixed histology, these differences were not statistically significant.
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


16. Ichihara S, Ikeda T, Kimura K, Hanatate F, Yamada F, Hasegawa M, Moritani S, Yatabe Y: Coincidence of mammary and sentinel lymph node papilloma. Am J Surg Pathol; 2008 May;32(5):784-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the mastectomy, the ipsilateral sentinel node was found to be extensively occupied by completely benign papilloma that measured 6 mm in its greatest dimension.
  • The clinical history led us to put forward the working hypothesis that the nodal papillary lesion may develop from the epithelial cells that are displaced from the mammary papillomas during needle procedures and mechanically transported to the sentinel lymph node.
  • The presence of myoepithelial layer in each papillary tumor was confirmed by immunostains with specific myoepithelial markers, p63 and CD10.
  • The excisional biopsy specimen exhibited displaced fragments of benign epithelial cells within granulation tissue at the needle manipulation site, indicating that iatrogenic epithelial cell displacement did occur in this case.
  • It remains undetermined whether the nodal papilloma was derived from the papilloma of the mastectomy or if it arose de novo from the breast tissue inclusion of the sentinel node.
  • [MeSH-minor] Axilla. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379415.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


17. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G, Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res; 2007 Dec;56(6):483-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
  • In this study, we observed depressed Smac/DIABLO and increased XIAP expression in ovarian epithelial tissues ordered by normal, benign and malignant epithelia.
  • In epithelial ovarian cancer (EOC), the expression of Smac/DIABLO decreased with the malignancy.
  • [MeSH-major] Drug Resistance, Neoplasm. Intracellular Signaling Peptides and Proteins / genetics. Mitochondrial Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacology. Apoptosis. Cell Line, Tumor. Female. Humans. Middle Aged. Ovary / metabolism. Paclitaxel / pharmacology. RNA, Messenger / metabolism. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Transfection. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029193.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Shaker OG, Ay El-Deen MA, Abd El-Rahim MT, Talaat RM: Gene expression of E-selectin in tissue and its protein level in serum of breast cancer patients. Tumori; 2006 Nov-Dec;92(6):524-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: This study aims to detect the expression of E-selectin in tissue and the serum level of its soluble form in patients with primary breast cancer and benign breast tumors and to correlate the results with the clinicopathological data of the subjects.
  • Group A comprised 30 patients with primary breast cancer, group B 9 patients with benign breast tumors, and group C 11 healthy control women undergoing reduction mammoplasty.
  • E-selectin gene expression was detected in 60%, 73.3% and 100% of patients with stage II, III and IV tumors, respectively.
  • E-selectin was found on the membranes of peritumoral endothelial cells while it was not found on breast epithelial cells.
  • CONCLUSIONS: The studied marker showed associations with established prognostic parameters such as lymph node involvement and histological tumor grade.
  • E-selectin can be regarded as a promising strategy in improving tumor therapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. E-Selectin / metabolism. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adolescent. Adult. Aged. Breast Diseases / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17260494.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / E-Selectin
  •  go-up   go-down


19. Kitagawa H, Okabayashi T, Nishimori I, Kobayashi M, Sugimoto T, Akimori T, Kohsaki T, Miyaji E, Onishi S, Araki K: Rapid growth of mucinous cystic adenoma of the pancreas following pregnancy. Int J Gastrointest Cancer; 2006;37(1):45-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At 8 mo postpartum, she became aware of an upper abdominal tumor.
  • The patient underwent tumor resection at 11 mo postpartum.
  • Pathological examination of the tumor revealed mucin-producing columnar epithelial cells lining the cystic wall with ovarian-type stromal tissue and no findings indicative of malignancy, giving a diagnosis of mucinous cystic adenoma of the pancreas.
  • Postpartum rapid growth of a benign mucinous cystic neoplasm might be linked to the production of female sex hormones during lactation.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1999 Feb;65(2):105-11 [9926740.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23 (4):410-22 [10199470.001]
  • [Cites] World J Surg Oncol. 2005 Sep 07;3:59 [16146567.001]
  • [Cites] Eur J Surg Oncol. 2005 Apr;31(3):282-7 [15780564.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):203-5 [15221374.001]
  • (PMID = 17290080.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ: Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol; 2010 Sep;203(3):228.e1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
  • OBJECTIVE: We sought to compare the Risk of Malignancy Index (RMI) to the Risk of Ovarian Malignancy Algorithm (ROMA) to predict epithelial ovarian cancer (EOC) in women with a pelvic mass.
  • RESULTS: At a set specificity of 75%, ROMA had a sensitivity of 94.3% and RMI had a sensitivity of 84.6% for distinguishing benign status from EOC (P = .0029).
  • [MeSH-major] Neoplasms, Glandular and Epithelial / diagnosis. Ovarian Neoplasms / diagnosis. Risk Assessment
  • [MeSH-minor] Algorithms. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Diagnostic Imaging. Epididymal Secretory Proteins / analysis. Female. Humans. Lymphatic Metastasis. Membrane Proteins / blood. Menopause. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):589-98 [16369985.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:30-4 [16515564.001]
  • [Cites] Cancer. 2007 May 15;109(10):2031-42 [17420977.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):225-9 [11330953.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):36-42 [11748973.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Obstet Gynecol. 1985 Apr;65(4):568-72 [3982731.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S4-14 [7835809.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S42-6 [7835810.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):9-12 [8995540.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):278-87 [10053096.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):447-61 [16126262.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7 [16515561.001]
  • (PMID = 20471625.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA105009; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / MUC16 protein, human; 0 / Membrane Proteins; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS235597; NLM/ PMC3594101
  •  go-up   go-down


21. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Non-neoplastic cysts were more common (343, 68.87%) than neoplastic tumours (155, 31.12%).
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • Krukenberg tumour, tumour metastatic to ovaries and non-Hodgkins lymphoma was also diagnosed during this period.
  • Malignant germ cell tumours were seen in much younger age group followed by sex cord stromal tumours.
  • Epithelial tumours were seen in much older age group.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


22. Zhong Y, Wang L, Li T, Chen XM: Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature. Chin J Dent Res; 2010;13(2):157-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumour showing malignant transformation: a case report and review of the literature.
  • Calcifying epithelial odontogenic tumour (CEOT) is a rare and benign odontogenic neoplasm that affects the jaws.
  • [MeSH-minor] Humans. Keratin-19 / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Odontogenic Tumors / pathology. Odontogenic Tumors / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21264368.001).
  • [ISSN] 1462-6446
  • [Journal-full-title] The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA)
  • [ISO-abbreviation] Chin J Dent Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-19; 0 / Ki-67 Antigen; Calcifying Epithelial Odontogenic Tumor
  •  go-up   go-down


23. Faquin WC, Cibas ES, Renshaw AA: "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts. Cancer; 2005 Apr 25;105(2):71-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Atypical" cells in fine-needle aspiration biopsy specimens of benign thyroid cysts.
  • Most are benign nodules with degenerative changes in a multinodular goiter.
  • Fine-needle aspiration biopsy (FNAB) specimens from these cystic nodules usually are easily interpreted as benign.
  • However, occasionally, cells with atypical features are encountered, increasing the possibility of a cystic malignant neoplasm.
  • To the authors' knowledge, the microscopic features of these benign cells, presumed to be of cyst-lining origin, have not been well described to date.
  • To refine the description of their morphologic features, with the belief that better recognition will avoid unnecessary surgery, the authors examined the cytologic and corresponding histologic features of thyroid cysts with "atypical" cells.
  • Seventy-five specimens with subsequent histologic correlation showing a benign cystic thyroid nodule were selected for study.
  • However, in 29% of these specimens, a papillary or Hurthle cell neoplasm could not be excluded.
  • The cytologic features of the atypical cells most often resembled classic reparative epithelial cells consistent with a cyst-lining origin.
  • In contrast to the atypical cells from benign cysts, cystic papillary carcinomas lacked the repair-like spindled cytomorphology, and showed nuclear crowding (100%), as well as papillary microarchitecture (50%), and rare intranuclear pseudoinclusions (42%).
  • Immunohistochemical staining of a subset of the resected thyroid cysts showed that the cyst-lining cells were positive for keratin and thyroglobulin, consistent with thyroid follicular cells.
  • CONCLUSIONS: Atypical cyst-lining cells were found to have characteristic features (e.g., distinct cell borders, elongated shape, eosinophilic cytoplasm, and distinct nucleoli) and lacked nuclear crowding, intranuclear pseudoinclusions, and papillary architecture that, in many specimens, allowed them to be recognized as benign.
  • The authors recommended that the subset of cells with the characteristic features described in the current study be reported as "consistent with benign cyst lining cells".
  • [MeSH-major] Biopsy, Fine-Needle. Cysts / pathology. Thyroid Diseases / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society.
  • [CommentIn] Cancer. 2006 Feb 25;108(1):72; author reply 73 [16400633.001]
  • (PMID = 15662703.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sampson N, Untergasser G, Lilg C, Tadic L, Plas E, Berger P: GAGEC1, a cancer/testis associated antigen family member, is a target of TGF-beta1 in age-related prostatic disease. Mech Ageing Dev; 2007 Jan;128(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Changes in TGF-beta signalling are implicated in prostate cancer (PCa) and benign prostatic hyperplasia (BPH), two of the most common diseases affecting ageing males.
  • We demonstrate GAGEC1 up-regulation by TGF-beta1 in primary prostatic stromal and epithelial cells.
  • [MeSH-major] Aging / physiology. Antigens, Neoplasm / metabolism. Prostatic Diseases / metabolism. Transforming Growth Factor beta1 / physiology

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113629.001).
  • [ISSN] 0047-6374
  • [Journal-full-title] Mechanisms of ageing and development
  • [ISO-abbreviation] Mech. Ageing Dev.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / M 903
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / PAGE4 protein, human; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


25. Liegl B, Hornick JL, Fletcher CD: Primary cutaneous PEComa: distinctive clear cell lesions of skin. Am J Surg Pathol; 2008 Apr;32(4):608-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor size ranged from 0.7 to 2 cm (median size, 1.5 cm).
  • Eight tumors were located on the limbs and 2 on the back.
  • The tumors involved the dermis and commonly showed infiltration into the subcutaneous fat.
  • Six tumors were composed of epithelioid cells and 4 showed mixed epithelioid and spindle cell morphology.
  • Tumor cells had clear, palely eosinophilic or granular cytoplasm.
  • Multinucleate tumor giant cells were observed in 3 cases.
  • In cases where HMB-45 was positive in fewer than 5% of tumor cells (5/10), microphthalmia transcription factor was positive in the majority of the tumor cell nuclei.
  • The other muscle markers (caldesmon, calponin) and also pan-keratin and epithelial membrane antigen were negative.
  • Primary cutaneous PEComas are rare and thus far apparently benign cutaneous tumors.
  • Accurate recognition of this entity is essential because of potential misdiagnosis as malignant tumors, especially malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Calcium-Binding Proteins / analysis. Calmodulin-Binding Proteins / analysis. Dermis / pathology. Desmin / analysis. Diagnosis, Differential. Female. Giant Cells / pathology. Humans. Immunohistochemistry. Keratins / analysis. MART-1 Antigen. Male. Melanoma-Specific Antigens. Microfilament Proteins / analysis. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Mitotic Index. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Subcutaneous Fat / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2016 Feb;38(2):165-6 [26825164.001]
  • (PMID = 18277881.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Calmodulin-Binding Proteins; 0 / Desmin; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microfilament Proteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / calponin; 68238-35-7 / Keratins
  •  go-up   go-down


26. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • Some types of mixed epithelial and stromal neoplasm are described and contrasted with carcinosarcoma.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


27. de Araújo VC, Altemani A, Furuse C, Martins MT, de Araújo NS: Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol; 2006 Nov;42(10):1011-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides its function, a tumor suppressor and a tumor facilitating functions have been attributed to this cell.
  • We investigated the immunoprofile of benign MC in intraductal areas of carcinoma ex-pleomorphic adenoma (CXPA), comparing them with the MC in duct-like areas of pleomorphic adenoma, origin of the malignant tumor.
  • The immunohistochemical reactions of all the antibodies showed stronger staining in benign MC surrounding the malignant epithelial cells than in benign MC in duct-like areas of pleomorphic adenoma, thus revealing that in the malignization process the benign MC become differentiated and produce important proteins related to the tumor suppressor function.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Cell Differentiation. Disease Progression. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757205.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


28. Dhall D, Al-Ahmadie H, Olgac S: Nested variant of urothelial carcinoma. Arch Pathol Lab Med; 2007 Nov;131(11):1725-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nested variant of urothelial carcinoma is a rare neoplasm that is histologically characterized by large numbers of small, closely packed, haphazardly arranged, poorly defined, confluent irregular nests of bland-appearing urothelial cells infiltrating the lamina propria and the muscularis propria.
  • Due to the cells' deceptively bland appearance, the tumors are sometimes misdiagnosed as benign lesions, leading in some cases to a significant delay in establishing the correct diagnosis and thus contributing to this neoplasm's advanced stage.
  • Nested variant of urothelial carcinoma must be differentiated from the benign proliferative lesions of urothelium, such as von Brunn nests, cystitis cystica, cystitis glandularis, nephrogenic adenoma, inverted papilloma, and paraganglioma.
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Keratin-20 / metabolism. Keratin-7 / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979494.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  • [Number-of-references] 14
  •  go-up   go-down


29. Fain-Kahn V, Poirot C, Uzan C, Prades M, Gouy S, Genestie C, Duvillard P, Morice P: Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod; 2009 Apr;24(4):850-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of ovarian cryopreservation in borderline ovarian tumours.
  • BACKGROUND: Borderline ovarian tumours (BOT) do not exhibit overt stromal invasion and are less aggressive than invasive epithelial ovarian tumours.
  • BOT also arise in younger patients than those who develop epithelial ovarian tumours.
  • METHODS: A retrospective study of data concerning young patients (less than 35 years of age) who underwent surgery for a BOT with OC planned during the surgical procedure.
  • RESULTS: Twenty-three patients, treated between January 2002 and February 2008, were initially selected but six of them were excluded from the present study (four because the tumour was malignant and two because it was benign).
  • CONCLUSION: In patients treated for a BOT, OC was eventually feasible in 53% of patients in whom this procedure was initially planned.
  • [MeSH-minor] Adolescent. Adult. Female. Fertility. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Pregnancy. Retrospective Studies. Transplantation, Autologous. Young Adult


30. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y: Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol; 2005 Nov;174(5):2046-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
  • PURPOSE: We assessed the differential expression of survivin and other apoptotic markers in stromal and epithelial compartments of benign prostatic hyperplasia (BPH) and normal prostate tissue.
  • RESULTS: Survivin and Bcl-2 expression increased incrementally from normal prostate to epithelial BPH to stromal BPH.
  • Caspase-3 expression was higher in BPH epithelium than in BPH stroma, which in turn was higher than that in normal prostate.
  • Ki-67 was significantly over expressed in BPH stroma and epithelium.
  • Survivin expression in BPH tissue correlated with International Prostate Symptom Score, quality of life, post-void residual urine volume, maximum urine flow rate and transforming growth factor-beta1 expression.
  • [MeSH-major] Caspases / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Prostatic Hyperplasia / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217391.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


31. Kobayashi K, Murakami R, Fujii T, Hirano A: Malignant transformation of ameloblastic fibroma to ameloblastic fibrosarcoma: case report and review of the literature. J Craniomaxillofac Surg; 2005 Oct;33(5):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ameloblastic fibrosarcoma is a rare malignant odontogenic tumour and is regarded as the malignant counterpart of the ameloblastic fibroma.
  • The epithelial component remains benign, but the mesenchymal component becomes malignant.
  • PATIENT: The case of a 26-year-old man who underwent curettage of an ameloblastic fibroma and died of an ameloblastic fibrosarcoma is presented, and the course of malignant transformation is analysed retrospectively.
  • Knowledge of the malignant potential in the mesenchymal spindle cells of ameloblastic fibroma will assist in determining the management of these benign tumours, and may prevent malignant transformation to ameloblastic fibrosarcoma.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Follow-Up Studies. Fractures, Spontaneous / pathology. Humans. Male. Mandibular Fractures / pathology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129612.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 16
  •  go-up   go-down


32. Kambham N, Kong C, Longacre TA, Natkunam Y: Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: a tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol; 2005 Dec;13(4):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it has not been widely tested in non-hematolymphoid tissues, and thus its utility in the setting of an undifferentiated malignant neoplasm has not been evaluated.
  • The authors conducted an extensive study of CD138 staining in over 1,700 normal, benign, and malignant non-hematolymphoid tissues, using five tissue microarrays.
  • In addition to the specific membrane staining, many normal tissues and epithelial tumors showed strong cytoplasmic immunoreactivity.
  • These results indicate that CD138 immunoreactivity is widespread in normal and neoplastic epithelial tissues, as well as a variety of undifferentiated epithelial and mesenchymal processes.
  • The authors conclude that the expression of syndecan-1, although relatively specific to plasma cells within the hematolymphoid system, should be interpreted with extreme caution in the setting of an undifferentiated neoplasm.
  • Furthermore, the two commercially available monoclonal CD138 antibodies tested in this study showed significant differences in their immunoreactivity in different tumor types.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280658.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans
  •  go-up   go-down


33. Puskas LG, Juhasz F, Zarva A, Hackler L Jr, Farid NR: Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand); 2005 Sep 5;51(2):177-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
  • Studies done to date have concentrated on single tumor types and thus provide no help in identifying tumor subtype specific markers.
  • To that end we have studied gene profiles of 5 types of benign and malignant thyroid nodular tissue (multinodular goiter, follicular adenoma, papillary and follicular carcinomas).
  • Despite the differences in the microarray panels used, we confirmed the differential regulation of 12 genes previously reported in thyroid cancer, although we found the expression of several genes to be regulated in other histological tumor subtypes than originally described.
  • We have thus identified new potential markers specific to malignant thyroid tumors.
  • It is apparent that a range of nodular thyroid tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples.
  • [MeSH-major] Gene Expression Profiling. Genes, Neoplasm. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / physiopathology. Adenoma / diagnosis. Adenoma / genetics. Adenoma / physiopathology. Biomarkers, Tumor / genetics. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / physiopathology. Gene Expression Regulation, Neoplastic. Goiter, Nodular / diagnosis. Goiter, Nodular / genetics. Goiter, Nodular / physiopathology. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171553.001).
  • [ISSN] 1165-158X
  • [Journal-full-title] Cellular and molecular biology (Noisy-le-Grand, France)
  • [ISO-abbreviation] Cell. Mol. Biol. (Noisy-le-grand)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Mizobuchi T, Masahiro N, Iwai N, Kohno H, Okada N, Nakada S: Clear cell tumor of the lung: surgical and immunohistochemical findings. Gen Thorac Cardiovasc Surg; 2010 May;58(5):243-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell tumor of the lung: surgical and immunohistochemical findings.
  • We encountered a clear cell tumor of the lung (CCTL) that was located peripherally, adjacent to the visceral pleura.
  • The tumor could be directly observed during surgery.
  • The in vivo color of the tumor was red, suddenly changing to white after the tumor was clamped.
  • Immunohistochemistry revealed tumor cells positive for vimentin and melanocytic markers (HMB-45 and melan-A) and negative for epithelial membrane antigen and cytokeratin.
  • With the absence of clinical findings in both kidneys, the tumor was diagnosed as a benign CCTL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Lung Neoplasms / chemistry. Lung Neoplasms / surgery. Perivascular Epithelioid Cell Neoplasms / chemistry. Perivascular Epithelioid Cell Neoplasms / surgery. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Female. Humans. Incidental Findings. MART-1 Antigen. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Tomography, X-Ray Computed. Treatment Outcome. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):517-9 [6733682.001]
  • [Cites] Ultrastruct Pathol. 2001 Nov-Dec;25(6):479-83 [11783912.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Apr;25(4):652-4 [15037292.001]
  • [Cites] Diagn Cytopathol. 2008 Feb;36(2):89-93 [18181192.001]
  • [Cites] J Korean Med Sci. 2008 Dec;23 (6):1121-4 [19119463.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1242-7 [9331299.001]
  • [Cites] Surg Today. 1998;28(9):985-7 [9744416.001]
  • (PMID = 20449716.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / Vimentin
  •  go-up   go-down


35. Abbas F, Memon A, Siddiqui T, Kayani N, Ahmad NA: Granular cell tumors of the urinary bladder. World J Surg Oncol; 2007;5:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the urinary bladder.
  • BACKGROUND: Granular cell tumors (GCTs) are extremely rare lesions of the urinary bladder with only nine cases being reported in world literature of which one was malignant.
  • Generally believed to be of neural origin based on histochemical, immunohistochemical, and ultrastructural studies; they mostly follow a clinically benign course but are commonly mistaken for malignant tumors since they are solid looking, ulcerated tumors with ill-defined margins.
  • MATERIALS AND METHODS: We herein report two cases of GCTs, one benign and one malignant, presenting with gross hematuria in a 14- and a 47-year-old female, respectively.
  • RESULTS: Histopathology revealed characteristic GCTs with positive immunostaining for neural marker (S-100) and negative immunostaining for epithelial (cytokeratin, Cam 5.2, AE/A13), neuroendocrine (neuron specific enolase, chromogranin A, and synaptophysin) and sarcoma (desmin, vimentin) markers.
  • The benign tumor was successfully managed conservatively with transurethral resection alone while for the malignant tumor, radical cystectomy, hysterectomy with bilateral salpingo-oophorectomy, anterior vaginectomy, plus lymph node dissection was done.
  • CONCLUSION: We recommend careful pathologic assessment for establishing the appropriate diagnosis and either a conservative or aggressive surgical treatment for benign or localized malignant GCT of the urinary bladder, respectively.
  • [MeSH-major] Cystoscopy / methods. Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Emergency Service, Hospital. Female. Follow-Up Studies. Hematuria / diagnosis. Hematuria / etiology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1973 Feb;109(2):101-11 [4124410.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1963 Oct;16:1202-13 [14079990.001]
  • [Cites] Br J Urol. 1961 Mar;33:76-9 [13683165.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):373-6 [9659502.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):48-58 [1985501.001]
  • [Cites] Br J Urol. 1985 Feb;57(1):109-10 [2982445.001]
  • [Cites] J Pathol. 1984 Mar;142(3):221-9 [6323661.001]
  • [Cites] Am J Pathol. 1983 Aug;112(2):139-46 [6192721.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1624-8 [6175391.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):239-48 [7189308.001]
  • [Cites] J Urol. 1974 Sep;112(3):343-5 [4368755.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] Am J Clin Pathol. 1971 Dec;56(6):736-49 [4108241.001]
  • [Cites] Cancer. 1971 Apr;27(4):948-55 [4102365.001]
  • [Cites] Hinyokika Kiyo. 1969 Jul;15(7):505-13 [4310526.001]
  • [Cites] J Urol. 1968 Dec;100(6):735-7 [4301412.001]
  • [Cites] Int J Urol. 2001 Jan;8(1):29-31 [11168695.001]
  • [Cites] BJU Int. 1999 Nov;84(7):871-2 [10532990.001]
  • (PMID = 17355632.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1828733
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


36. Jaffar R, Mohanty SK, Khan A, Fischer AH: Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal; 2009;6:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms.
  • BACKGROUND: Published criteria to distinguish benign colloid nodules from follicular neoplasms emphasize only three interdependent features: size of follicles, amount of colloid, and cellularity.
  • Three of these four had equivocal features of a benign colloid nodule histologically.
  • Hemosiderin within follicular epithelial cells was present in 18% (18 of 101) of goiters, whereas none of the 64 follicular neoplasms had intraepithelial hemosiderin (P<.0003).
  • CONCLUSIONS: If papillary thyroid carcinoma and Hürthle cell neoplasm are ruled out, our findings indicate that the presence of hemosiderin virtually excludes a clinically significant follicular neoplasm.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytojournal. 2008;5:6 [18394201.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):525-8 [17636488.001]
  • [Cites] Cytopathology. 2007 Apr;18(2):105-11 [17397495.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):171-9 [10390065.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):142-6 [1542996.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):53-60 [2916371.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1164-70 [3943039.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):345-51 [2343690.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • (PMID = 19495407.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2678825
  • [Keywords] NOTNLM ; Benign colloid nodule / follicular cells / hemosiderin laden macrophages / hemosiderin within follicular neoplasms / macrophages
  •  go-up   go-down


37. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gätje R, Karn T, Kaufmann M: Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer; 2005 Dec;12(4):903-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene.
  • A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma as compared with benign mammary epithelial cells.
  • The loss of ER-beta resulted in abnormal growth of mammary epithelial cells.
  • In contrast to benign breast, more than two-thirds of invasive breast cancers showed a high degree of methylation.
  • By analysis of breast tumors, previously characterized by gene-expression profiling, methylation was predominantly detected in a subgroup of patients with an unfavorable prognosis, suggesting a possible prognostic value of the ER-beta methylation status.
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / genetics. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Profiling. Humans. Molecular Sequence Data. Prognosis. RNA, Small Interfering / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322330.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Estrogen Receptor beta; 0 / RNA, Small Interfering
  •  go-up   go-down


38. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diseases mimicking advanced-stage epithelial ovarian cancer].
  • [Transliterated title] Afecţiuni mimând cancerul ovarian epitelial în stadiu avansat.
  • This paper draws attention towards 3 cases with different pathologies all of which suggesting however both clinically and by imaging means as the most likely diagnosis advanced-stage epithelial ovarian cancer since all these three postmenopausal women had been admitted to the hospital with ascites, pelvic masses and deterioration of the physical wellbeing (fatigue, decreased appetite, weight loss, pallor).
  • Findings during exploratory laparotomy on all these three pacients included ascites (hemorragic in one case) diffuse tumorous implants throughout the abdominal and pelvic peritoneal surfaces (in two cases) and the ovarian tumour.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • Moreover, nonmalignant ovarian tumours were certified in all three cases under current presentation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome


39. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ: Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med; 2006 Oct;130(10):1516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
  • CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma.
  • Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features.
  • However, histologic classification does not always predict outcome.
  • Objective.-To determine the prognostic value of a variety of clinicopathologic features and immunoreactivities in PTs.
  • DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
  • Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
  • RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant).
  • One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis.
  • The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs.
  • Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs.
  • Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors.
  • CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / metabolism. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090194.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


40. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • Expression of Ki-67 antigen has been used to compare proliferative activity of mammary fibroadenoma epithelium in the follicular and luteal phases of the menstrual cycle.
  • MATERIALS AND METHODS: Ninety eumenorrheic women were selected for tumour excision; they were assigned to either of the two groups, according to their phase of menstrual cycle.
  • At the end of the study, 75 patients with 87 masses were evaluated by epithelial cell Ki-67 expression, blind (no information given concerning group to which any lesion belonged).
  • Median tumour size was 2.0 cm and no relationship between proliferative activity and nodule diameter was observed.
  • Average values for expression of Ki-67 (per 1000 epithelial cells) in follicular and luteal phases were 27.88 and 37.88, respectively (P = 0.116).
  • CONCLUSION: Our findings revealed that proliferative activities in the mammary fibroadenoma epithelium did not present a statistically significant difference in the follicular and luteal phases.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


41. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


42. Tanahashi J, Kashima K, Daa T, Kondo Y, Kuratomi E, Yokoyama S: A case of cutaneous myoepithelial carcinoma. J Cutan Pathol; 2007 Aug;34(8):648-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cutaneous myoepithelioma, both benign and malignant, is a rare neoplasm composed of neoplastic myoepithelial cells showing diverse histopathological features, and criteria for discriminating benign or malignant have not been fully clarified.
  • RESULTS: Resected tumor was located in the whole dermis and subcutis.
  • Tumor cells were all epithelioid, although plasmacytoid and glycogen-rich clear cells were also observed within the large nodules of the deep part.
  • Immunohistochemically, the cells were positive for both epithelial and myogenic markers, suggesting myoepithelial origin.

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640237.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


43. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol; 2005 Jul 15;175(2):1197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK.
  • Tumor-associated macrophages may influence tumor progression, angiogenesis and invasion.
  • To investigate mechanisms by which macrophages interact with tumor cells, we developed an in vitro coculture model.
  • Previously we reported that coculture enhanced invasiveness of the tumor cells in a TNF-alpha- and matrix metalloprotease-dependent manner.
  • We report that coculture of macrophages with ovarian or breast cancer cell lines led to TNF-alpha-dependent activation of JNK and NF-kappaB pathways in tumor cells, but not in benign immortalized epithelial cells.
  • Tumor cells with increased JNK and NF-kappaB activity exhibited enhanced invasiveness.
  • Inhibition of the NF-kappaB pathway by TNF-alpha neutralizing Abs, an NF-kappaB inhibitor, RNAi to RelA, or overexpression of IkappaB inhibited tumor cell invasiveness.
  • Cocultured tumor cells were screened for the expression of 22 genes associated with inflammation and invasion that also contained an AP-1 and NF-kappaB binding site.
  • EMMPRIN and MIF were up-regulated in cocultured tumor cells in a JNK- and NF-kappaB-dependent manner.
  • Knocking down either MIF or EMMPRIN by RNAi in the tumor cells significantly reduced tumor cell invasiveness and matrix metalloprotease activity in the coculture supernatant.
  • We conclude that TNF-alpha, via NF-kappaB, and JNK induces MIF and EMMPRIN in macrophage to tumor cell cocultures and this leads to increased invasive capacity of the tumor cells.
  • [MeSH-major] Epithelial Cells / pathology. JNK Mitogen-Activated Protein Kinases / physiology. Macrophages / immunology. NF-kappa B / physiology. Neoplasm Invasiveness
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, CD / genetics. Antigens, CD / physiology. Antigens, CD147. Binding Sites / genetics. Breast Neoplasms / immunology. Breast Neoplasms / pathology. Cell Line, Transformed. Cell Line, Tumor. Cells, Cultured. Coculture Techniques. Female. Humans. Macrophage Migration-Inhibitory Factors / antagonists & inhibitors. Macrophage Migration-Inhibitory Factors / biosynthesis. Macrophage Migration-Inhibitory Factors / physiology. Matrix Metalloproteinases / secretion. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. RNA Interference / physiology. Transcription Factor RelA. Up-Regulation / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002723.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BSG protein, human; 0 / Macrophage Migration-Inhibitory Factors; 0 / NF-kappa B; 0 / Transcription Factor RelA; 136894-56-9 / Antigens, CD147; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


44. Saran R, Tiwari RK, Reddy PP, Ahuja YR: Risk assessment of oral cancer in patients with pre-cancerous states of the oral cavity using micronucleus test and challenge assay. Oral Oncol; 2008 Apr;44(4):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral cancer is preceded by some benign lesions or conditions, which are termed pre-cancerous.
  • MNT and comet assay were carried out on buccal epithelial cells.
  • A significant stepwise increase in the DNA damage (basal/MNNG-treated/post-repair) was observed in buccal epithelial cells and peripheral blood leucocytes from control to pre-cancer patients and from pre-cancer to cancer patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Aberrations. Comet Assay / methods. DNA Damage. DNA Repair. DNA, Neoplasm / genetics. Disease Progression. Female. Humans. Leukocytes / drug effects. Leukocytes / pathology. Male. Methylnitronitrosoguanidine / pharmacology. Micronucleus Tests / methods. Middle Aged. Mouth Mucosa / pathology. Risk Assessment / methods

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2008 Jul;44(7):716-7 [18381248.001]
  • (PMID = 17936677.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 12H3O2UGSF / Methylnitronitrosoguanidine
  •  go-up   go-down


45. Bousdras VA, Bousdras KA, Newman L: Nasal obstruction as the first symptom in a patient with a calcifying epithelial odontogenic tumour (CEOT). Dent Update; 2009 Jul-Aug;36(6):350-2, 355
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal obstruction as the first symptom in a patient with a calcifying epithelial odontogenic tumour (CEOT).
  • Calcifying epithelial odontogenic tumour (CEOT), also known as Pindborg tumour, is a rare, benign odontogenic neoplasm.
  • Dental practitioners might be the first clinicians to come across such tumours, during investigation of missing or non-erupted maxillary teeth, ie canines, and they should be alerted by any unilateral nasal obstruction symptoms.
  • Diagnostic features and treatment options of the tumour are discussed in relation to its histological typing.
  • [MeSH-major] Maxillary Neoplasms / complications. Maxillary Sinus Neoplasms / complications. Nasal Obstruction / etiology. Odontogenic Tumors / complications. Odontogenic Tumors / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19743664.001).
  • [ISSN] 0305-5000
  • [Journal-full-title] Dental update
  • [ISO-abbreviation] Dent Update
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Yang HW, Cao J, Yang NW, Liu JL, Zhang CM, Chen JS, Hong JS, Jiang Y, Su JJ: [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance]. Ai Zheng; 2005 Jul;24(7):842-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance].
  • This study was to explore the expression and significance of small breast epithelial mucin (SBEM) mRNA, the specific marker of breast cancer, in peripheral blood of breast cancer patients.
  • METHODS: Expression of SBEM mRNA in peripheral blood samples from 67 breast cancer patients, 16 benign breast disease patients, and 20 healthy volunteers was detected by nested reverse transcription-polymerase chain reaction (nested RT-PCR).
  • RESULTS: SBEM mRNA was not detected in healthy volunteers and benign breast disease patients.
  • The expression of SBEM mRNA in peripheral blood was not correlated with patient's age, primary tumor size, pathologic type, and estrogen or progestin receptor status (P0.05).
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Female. Fibroma / metabolism. Fibroma / pathology. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Estrogen / blood. Receptors, Progesterone / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004812.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUCL1 protein, human; 0 / Mucins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


47. King J, Thatcher N, Pickering C, Hasleton P: Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology; 2006 Dec;49(6):561-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
  • AIMS: A systematic review of published reports that have evaluated the ability of immunohistochemistry and argyrophil nucleolar organizing region (AgNOR) staining to distinguish between benign and malignant pleural disease.
  • Desmin and epithelial membrane antigen (EMA) were the most useful, with sensitivity and specificity both above 74%.
  • A high MCM2 labelling index also differentiated between benign and malignant pleural disease.
  • The diagnostic importance of histological features seen on plain tissue sections is emphasized as vital for correctly differentiating between benign pleural disease and malignant pleural mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunohistochemistry / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Silver Staining
  • [MeSH-minor] Antigens, Nuclear. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Nuclear Proteins. Nucleolus Organizer Region / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163840.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Nuclear; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  • [Number-of-references] 33
  •  go-up   go-down


48. Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P: Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer; 2010 Jun;46(9):1661-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied immunohistochemical nuclear and/or cytoplasmic expression of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine, as well as major antioxidative enzymes peroxiredoxins (PRDX) I-VI and thioredoxin (TXN) in ovarian tumours.
  • The material consisted of 20 benign (10 serous, 10 mucinous) and 51 borderline (33 serous, 18 mucinous) epithelial ovarian tumours.
  • The markers of oxidative stress, 8-OHdG and nitrotyrosine, were seen already in benign tumours (in 20% and 45% of the tumours, respectively) and their expression patterns were similar in benign and borderline tumours.
  • The levels of PRDX II, III, IV, V and VI were significantly higher in borderline than in benign tumours (p<0.02 for all).
  • Specifically for PRDX II (for both nuclear and cytoplasmic expression, p<0.00005) and PRDX VI (for cytoplasmic expression, p=0.0003 and for nuclear expression, p=0.0005) the difference between benign and borderline tumours was remarkable.
  • In general, serous benign and borderline tumours expressed higher antioxidant enzyme levels than mucinous ones.
  • Nuclear TXN was expressed more strongly in benign than in borderline tumours (p=0.003).
  • Oxidative stress occurs already in benign ovarian tumours and the levels are comparable to borderline tumours.
  • However, some of the antioxidant enzymes, especially PRDX II and VI, are more profoundly induced in borderline ovarian tumours, reflecting their possible role as cancer preventers.
  • This difference could also offer a potential tool for differential diagnosis between benign and borderline epithelial ovarian tumours.
  • [MeSH-major] Antioxidants / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / enzymology. Oxidative Stress / physiology
  • [MeSH-minor] Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Female. Humans. Immunohistochemistry. Peroxiredoxins / metabolism. Reactive Oxygen Species / metabolism. Thioredoxins / metabolism. Tyrosine / analogs & derivatives. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206498.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Reactive Oxygen Species; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 52500-60-4 / Thioredoxins; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 1.11.1.15 / Peroxiredoxins; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


49. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


50. Radotra B, Awasthi A, Joshi K, Das A: Histopatholgical spectrum of thymic neoplasms: twelve-year experience at a referral hospital in north India. Indian J Pathol Microbiol; 2006 Jan;49(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 96 thymectomy specimens were received during the study period (1992-2004), which consisted of 54 neoplasms and 42 benign lesions.
  • Among the neoplasms there were 48 thymic epithelial tumors, 3 thymolipomas and 3 thymic carcinoids.
  • Among paraneoplastic syndromes in thymic epithelial tumours, 27 out of 48 (56.25%) cases were associated with myasthenia gravis and one case was associated with pure red cell aplasia.
  • The most frequent histological subtype was cortical thymoma (43.24%) followed by predominantly cortical (24.32%) and well-differentiated thymic carcinoma (18.92%).
  • On staging, all cases of mixed and predominantly cortical subtype were stage 1 whereas one medullary and 2 cortical thymomas and 4 well differentiated thymic carcinoma (WDTC) showed pleural and pericardial invasion (stage III).
  • This study has revealed that half of thymic epithelial tumours presented as myasthenia gravis.
  • The cortical thymoma was the most frequently encountered histologic subtype and most commonly associated with myasthenia gravis.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoma / pathology. Child. Child, Preschool. Female. Humans. India. Lipoma / pathology. Male. Middle Aged. Myasthenia Gravis. Neoplasm Staging. Red-Cell Aplasia, Pure. Thymectomy. Thymoma / pathology. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625962.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


51. Iezzi G, Piattelli A, Rubini C, Artese L, Fioroni M, Carinci F: MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolaryngol Ital; 2007 Oct;27(5):237-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odontogenic myxoma is a rare benign neoplasm occurring in the jaws.
  • In some cases (20%), odontogenic epithelial islands may be found.
  • The Authors evaluated p53, MIB-1, and Bcl-2 expressed by the epithelial and stromal elements in 12 cases of odontogenic myxoma of the jaws.
  • The cells of the odontogenic epithelium were positive for Bcl-2, p53 and MIB-1.
  • Proliferation of both the epithelial and stromal components could be related to the growth of this odontogenic tumour.
  • [MeSH-major] Genes, bcl-2 / genetics. Genes, p53 / genetics. Mandibular Neoplasms / genetics. Mandibular Neoplasms / pathology. Myxoma / genetics. Myxoma / pathology. Odontogenic Tumors / genetics. Odontogenic Tumors / pathology. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Humans. Middle Aged. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 2002 Aug;31(7):415-20 [12165060.001]
  • [Cites] Life Sci. 2003 Oct 17;73(22):2865-72 [14511771.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Dec;61(12):1463-6 [14663812.001]
  • [Cites] Oncol Res. 2005;15(5):249-55 [16261844.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):375-81 [16309543.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4699-706 [16334163.001]
  • [Cites] J Clin Periodontol. 2006 Jan;33(1):76-8 [16367860.001]
  • [Cites] J Oral Pathol Med. 2006 Jul;35(6):369-75 [16762018.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):750-5 [16690252.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Sep;64(9):1343-52 [16916667.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Jun;32(3):161-5 [15113574.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jun;33(4):333-7 [15145033.001]
  • [Cites] Oral Oncol. 2004 Oct;40(9):954-9 [15380175.001]
  • [Cites] J Clin Pathol. 1973 Aug;26(8):570-82 [4354841.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1975 Jun;39(6):901-17 [1055976.001]
  • [Cites] J Oral Pathol. 1977 Nov;6(6):343-58 [412928.001]
  • [Cites] J Oral Pathol. 1985 Apr;14(4):299-306 [3923172.001]
  • [Cites] J Maxillofac Surg. 1986 Feb;14(1):46-52 [3456413.001]
  • [Cites] J Oral Pathol Med. 1991 Mar;20(3):114-9 [2037972.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(5):377-83 [1375793.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):126-31 [7913362.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):138-41 [8032302.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):377-80 [7536506.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):419-23 [7719225.001]
  • [Cites] J Oral Maxillofac Surg. 1995 May;53(5):518-21 [7722719.001]
  • [Cites] Mod Pathol. 1995 Feb;8(2):150-4 [7777475.001]
  • [Cites] Histopathology. 1995 Mar;26(3):219-28 [7797199.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):759-62 [7560205.001]
  • [Cites] J Oral Pathol Med. 1995 Aug;24(7):313-5 [7473268.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Jun;24(3):221-5 [7594756.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):102-10 [8617450.001]
  • [Cites] J Pathol. 1996 Apr;178(4):393-7 [8691316.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):143-9 [8762869.001]
  • [Cites] Cancer Lett. 1996 Aug 2;105(2):139-46 [8697436.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):380-3 [8746268.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):392-5 [8746270.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):403-4 [8746274.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):426-33 [8899782.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):328-32 [8944836.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Nov;32B(6):394-400 [9039223.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Pathol Res Pract. 1997;193(1):1-7 [9112268.001]
  • [Cites] J Pathol. 1997 Aug;182(4):392-7 [9306959.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Dec;84(6):672-5 [9431538.001]
  • [Cites] Oral Oncol. 1997 Nov;33(6):419-25 [9509126.001]
  • [Cites] Pathol Res Pract. 1998;194(5):309-17 [9651943.001]
  • [Cites] J Pathol. 1998 Apr;184(4):360-8 [9664901.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):191-6 [9682980.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4415-7 [9891502.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):716-24 [10023332.001]
  • [Cites] Mol Pathol. 1998 Oct;51(5):254-61 [10193519.001]
  • [Cites] J Oral Pathol Med. 2005 Jan;34(1):46-52 [15610406.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):191-5 [15660091.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):257-62 [15817067.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):811-9 [15944979.001]
  • [Cites] Int Endod J. 2005 Jul;38(7):465-9 [15946267.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):432-5 [16053855.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2589-92 [16080498.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):204-11 [16001434.001]
  • [Cites] J Oral Pathol Med. 2005 Nov;34(10):602-7 [16202080.001]
  • [Cites] Head Neck. 2005 Nov;27(11):982-9 [16136583.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1157-62 [16254104.001]
  • [Cites] Semin Diagn Pathol. 1999 Nov;16(4):297-301 [10587272.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):129-38 [10738940.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):139-44 [10738941.001]
  • [Cites] J Laryngol Otol. 2000 Jul;114(7):533-5 [10992937.001]
  • (PMID = 18198753.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2640038
  •  go-up   go-down


52. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • FACS (fluorescence activated cell sorting) analysis enabled the selection of CD133(+) cells, whose epithelial origin was confirmed by immunofluorescence analysis with monoclonal anti-cytokeratin 7.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


54. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C: Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand; 2009;88(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine whether urine can be used to measure specific ovarian cancer proteomic profiles and whether one peak alone or in combination with other peaks or CA125 has the sensitivity and specificity to discriminate between ovarian cancer pelvic mass and benign pelvic mass.
  • Of the women, 156 had benign gynaecological tumors, 13 had borderline tumors and 40 had malignant epithelial ovarian cancer.
  • RESULTS: Benign and malignant ovarian cancer cases were compared; 21 significantly different peaks (p<0.001) were visualized using Mann-Whitney analysis, ranging in m/z values from 1,500 to 185,000.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-125 Antigen / analysis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Biopsy, Needle. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pelvic Neoplasms / blood. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / urine. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Proteomics. ROC Curve. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023702.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


55. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol; 2006 Dec 15;177(12):8730-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine, is overexpressed in prostate cancer, but the mechanism by which MIF exerts effects on tumor cells remains undetermined.
  • Therefore, we hypothesized that increased expression or surface localization of CD74 and MIF overexpression by prostate cancer cells regulated tumor cell viability.
  • Prostate cancer cell lines (LNCaP and DU-145) had increased MIF gene expression and protein levels compared with normal human prostate or benign prostate epithelial cells (p < 0.01).
  • In DU-145 xenografts, ISO-1 significantly decreased tumor volume and tumor angiogenesis.
  • [MeSH-major] Antigens, Differentiation, B-Lymphocyte / physiology. Cell Proliferation. Histocompatibility Antigens Class II / physiology. Macrophage Migration-Inhibitory Factors / physiology. Neoplasm Invasiveness / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Intramolecular Oxidoreductases / antagonists & inhibitors. Intramolecular Oxidoreductases / physiology. Isoxazoles / pharmacology. Male. Mice. Neoplasm Proteins. Signal Transduction. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17142775.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Histocompatibility Antigens Class II; 0 / Isoxazoles; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / invariant chain; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


56. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary


57. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • Moreover, CEA and mammaglobin were specifically expressed in epithelial malignancies, and mammaglobin was mainly expressed in effusions from breast carcinoma (97.3% of specificity).
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


58. Ponnamperuma RM, King KE, Elsir T, Glick AB, Wahl GM, Nister M, Weinberg WC: The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation. J Pathol; 2009 Oct;219(2):263-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional regulation by p53 is critical for p53-mediated tumour suppression; however, p53-mediated transactivation has been dissociated from p53-mediated biological processes including apoptosis, DNA repair, and differentiation.
  • We compared the effects of a mutant allele, p53(QS - val135), containing a double mutation in the amino-terminus abrogating transactivation activity and a modification at amino acid 135 partially affecting DNA binding, to complete loss of p53.
  • We applied in vitro endpoints correlated with epithelial tumourigenesis and an in vivo assay of tumour phenotype to assess whether loss of p53-mediated transcriptional regulation underlies the malignant phenotype of p53(-/-)/v-ras(Ha)-overexpressing keratinocytes.
  • The tumours arising in p53(QS - val135/QS - val135) keratinocytes displayed strong nuclear p53 expression; thus, the p53(QS - val135) allele was maintained and the deficient transactivation function of the expressed p53QS mutant protein was supported by absence of p21(waf1) in these tumours.
  • The p53(QS - val135) allele did not confer a dominant-negative phenotype, as p53(+/QS - val135) keratinocytes senesced normally in response to v-ras(Ha) expression and formed benign tumours.
  • Furthermore, TGF-beta enhances p53QS-induced activation of a dual p53-TGF-beta responsive reporter in a keratinocyte cell line.
  • These findings support an essential role for p53-mediated transcriptional regulation in suppressing malignancies arising from ras-induced skin tumours, consistent with previous findings in spontaneous carcinogenesis in other organs, and highlight the potential importance of senescence for tumour suppression in vivo.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [Cites] Oncogene. 2000 Mar 23;19(13):1698-709 [10763827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1215-20 [18216268.001]
  • [Cites] EMBO J. 2000 Sep 15;19(18):4967-75 [10990460.001]
  • [Cites] Cell Growth Differ. 2000 Nov;11(11):561-71 [11095245.001]
  • [Cites] Nat Med. 2002 Mar;8(3):282-8 [11875500.001]
  • [Cites] Biochimie. 2002 Jan;84(1):83-93 [11900880.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):577-90 [12667443.001]
  • [Cites] Cell. 2003 May 2;113(3):301-14 [12732139.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2596-605 [12750285.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3635-44 [12789272.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S55-63 [14508081.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):235-43 [15145576.001]
  • [Cites] Nature. 1986 Oct 30-Nov 5;323(6091):822-4 [2430189.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Cell. 1990 Aug 24;62(4):671-80 [2143698.001]
  • [Cites] Genes Dev. 1991 Feb;5(2):151-9 [1995413.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • [Cites] Science. 1992 May 8;256(5058):827-30 [1589764.001]
  • [Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5584-92 [7923201.001]
  • [Cites] Genes Dev. 1994 Oct 15;8(20):2429-40 [7958907.001]
  • [Cites] Nat Genet. 1995 Mar;9(3):305-11 [7773294.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2271-9 [7784075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Oncogene. 1997 May 29;14(21):2511-20 [9191051.001]
  • [Cites] Oncogene. 1997 Aug 7;15(6):685-90 [9264409.001]
  • [Cites] Mol Carcinog. 1998 Jan;21(1):50-61 [9473771.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13030-6 [9582339.001]
  • [Cites] Oncogene. 1999 Mar 25;18(12):2149-55 [10321740.001]
  • [Cites] Curr Opin Oncol. 2005 Jan;17(1):49-54 [15608513.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):145-52 [15654339.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3563-73 [15750633.001]
  • [Cites] Expert Opin Biol Ther. 2006 Jan;6(1):55-61 [16370914.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2881-4 [16540631.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):395-6; author reply 396-7 [16570054.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9051-6 [16757565.001]
  • [Cites] Science. 2007 Feb 9;315(5813):840-3 [17234915.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(23):8228-42 [17875924.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):37-43 [10973245.001]
  • (PMID = 19718706.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100845; United States / NCI NIH HHS / CA / R01 CA100845-05; United States / FDA HHS / BO / Z01 BO04006-06
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS146961; NLM/ PMC4208754
  •  go-up   go-down


59. Cerdá-Nicolás M, Löpez-Gines C, Gil-Benso R, Benito R, Pellin A, Ruiz-Saurí A, Sanchos-Garcia J, Roldan P, Talamantes F, Barberá J: Solitary fibrous tumor of the orbit: morphological, cytogenetic and molecular features. Neuropathology; 2006 Dec;26(6):557-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the orbit: morphological, cytogenetic and molecular features.
  • Solitary fibrous tumor (SFT), a benign neoplasm arising in mesenchymal structures, was initially described in the pleura but subsequently has also been documented in other locations.
  • It is uncommon in the orbit, where it closely resembles other benign spindle-shaped mesenchymal tumors of this area such as schwannoma, meningioma or hemangiopericytoma.
  • The neoplastic cells were intensely positive for CD34 and vimentin, while S100, epithelial membrane antigen (EMA), Caldesmon, Calretinin and WT-1 proved negative.
  • Measurement of DNA content revealed a DNA index of 1, indicating a diploid peak in 95% of the tumor cells.
  • No p14(ARF), p15(INK4B) and p16(INK4A) deletions or hypermethylation were observed in this benign tumor.
  • Following surgical resection and radiotherapy, the patient showed no tumor relapse after one year of follow-up.
  • [MeSH-minor] Adult. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Exons / genetics. Female. Gene Deletion. Genes, p53 / genetics. Humans. Magnetic Resonance Imaging. Point Mutation. Proto-Oncogene Proteins c-mdm2 / genetics. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology. Tumor Suppressor Protein p14ARF / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203593.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p14ARF; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


60. Plaza JA, Wakely PE Jr, Suster S: Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. Am J Surg Pathol; 2006 Mar;30(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation.
  • Benign nerve sheath tumors of soft tissue can occasionally adopt unusual or unfamiliar morphologic appearances that may introduce difficulties for diagnosis, such as multinucleation, bizarre nuclei, intranuclear vacuoles, and other degenerative changes.
  • Tumor cells adopting a signet-ring or lipoblast-like configuration, however, are mostly associated with epithelial malignancies, liposarcoma and melanoma, and have been only rarely observed in spindle cell tumors of soft tissue.
  • We report 5 cases of benign nerve sheath neoplasms that displayed prominent signet-ring cells with lipoblast-like features.
  • Four tumors predominantly showed features of schwannoma and one of neurofibroma; however, intimately admixed with the spindle cell population, there were also numerous scattered mature adipocytes as well as lipoblast-like cells displaying a signet-ring cell appearance.
  • The presence of mature fat and signet-ring lipoblast-like cells within a nerve sheath neoplasm is quite rare and may signify a process of aberrant differentiation.
  • Neurogenic tumors should be added in the differential diagnosis of spindle cell tumors capable of displaying prominent signet-ring cell features.

  • Genetic Alliance. consumer health - Nerve sheath neoplasm.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Karim RZ, Gerega SK, Yang YH, Horvath L, Spillane A, Carmalt H, Scolyer RA, Lee CS: Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. J Clin Pathol; 2009 Nov;62(11):1016-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours.
  • BACKGROUND: The Wnt pathway is important in cell signalling transduction and is involved in the pathogenesis of multiple tumour types.
  • A comprehensive analysis of the expression of Wnt signalling pathway proteins in mammary phyllodes tumours (PTs) has not been previously performed.
  • AIMS: To evaluate the immunohistochemical expression of Wnt pathway proteins in a cohort of PTs, to determine their role in tumour pathogenesis and to identify any associations with patient outcome.
  • METHODS: 65 PTs (34 benign, 23 borderline and 8 malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • Stroma and epithelium were scored separately.
  • Epithelial membranous and stromal nuclear beta-catenin, epithelial cytoplasmic Wnt1 and epithelial E-cadherin all also showed increasing expression with increasing tumour grade, however, the differences were not significant.
  • Disease-free survival was significantly decreased (p = 0.0017) with positive epithelial E-cadherin staining.
  • CONCLUSIONS: Results suggest that alterations in the Wnt pathway are important in the progression and in the epithelial and stromal interactions in PTs.
  • They have important implications for understanding the pathogenesis of these uncommon but clinically important tumours.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Phyllodes Tumor / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Cadherins / metabolism. Cohort Studies. Disease Progression. Female. Humans. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Signal Transduction / physiology. Survival Analysis. Tissue Array Analysis / methods. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861560.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / SFRP4 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


62. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M: Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem; 2007 Aug;55(8):867-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy.
  • In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125.
  • Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively.
  • However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled.
  • [MeSH-major] Antibodies. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Glycoproteins / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Drug Carriers. Female. Humans. Mucin-1. Neoplasms, Glandular and Epithelial / metabolism. Ovary / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478446.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Drug Carriers; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins; 0 / tumor-associated antigen 72
  •  go-up   go-down


63. Haberal A, Cil AP, Gunes M, Cavusoglu D: Papillary adenofibroma of the cervix: a case report. Ultrasound Obstet Gynecol; 2005 Aug;26(2):186-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenofibroma is an extremely rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • Preoperative diagnosis of this tumor is usually difficult.
  • We describe the case of a 55-year-old woman with papillary cervical adenofibroma, which appeared as a cervical mass containing multiple cystic components on transvaginal ultrasound.
  • This lesion appears to be clinically and histologically benign but must be differentiated from malignant lesions of the uterus, particularly from adenosarcoma, which can be suggestive of adenofibroma.
  • Accurate diagnosis of these benign tumors permits appropriate counseling of patients.


64. Sato M, Irisawa A, Bhutani MS, Schnadig V, Takagi T, Shibukawa G, Wakatsuki T, Imamura H, Takahashi Y, Sato A, Hikichi T, Obara K, Hashimoto Y, Watanabe K, Ohira H: Gastric bronchogenic cyst diagnosed by endosonographically guided fine needle aspiration biopsy. J Clin Ultrasound; 2008 May;36(4):237-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a gastric bronchogenic cyst diagnosed via endosonographically guided fine-needle aspiration (EUS-FNA) biopsy.
  • A 60-year-old woman was referred to our hospital for an endoscopic ultrasound (EUS) examination because of a gastric subepithelial lesion detected by upper gastrointestinal endoscopy.
  • The latter finding raised concerns that the lesion might represent a cystic neoplasm rather than a simple cyst.
  • Cytologic evaluation of aspirated material revealed the presence of benign-appearing ciliated columnar epithelial cells within a mucinous background.
  • [MeSH-major] Bronchogenic Cyst / pathology. Endosonography. Stomach Diseases / pathology. Ultrasonography, Interventional

  • Genetic Alliance. consumer health - Bronchogenic Cyst.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. J Clin Ultrasound, 2008.
  • (PMID = 18027836.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Norimatsu Y, Miyamoto T, Kobayashi TK, Oda T, Moriya T, Yanoh K, Miyake Y, Ohno E: Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions. Diagn Cytopathol; 2008 Apr;36(4):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of thin-layer preparations in endometrial cytology: immunocytochemical expression of PTEN, beta-catenin and p53 for benign endometrial lesions.
  • Immunocytochemical expression of PTEN, beta-catenin, and p53 were investigated using 30 cases each of proliferative endometrium (PE), secretory endometrium (SE), atrophic endometrium (AE), and EGBD.PTEN expression of normal endometrial glandular epithelial cells changes with the hormonal status; PE produce very high expression, SE creates attenuation or disappearance of PTEN expression and AE diminished more in comparison with SE.
  • As for the immunoreactivity of beta-catenin, in all phases (PE, SE, AE, and EGBD), it was observed in the cytoplasm of glandular epithelial cells, but not nuclei, and showed strong membranous staining.
  • As for the p53 immunoreactivity, p53 positivity was not observed in the glandular epithelial cells in all phases (PE, SE, AE, and EGBD) with the exception of some metaplastic cells.
  • The presence of p53 immunoreactivity of a weak, low ratio in metaplastic cells was unexpected.
  • [MeSH-major] Endometrium / cytology. Epithelial Cells / cytology. Epithelial Cells / metabolism. PTEN Phosphohydrolase / metabolism. Tumor Suppressor Protein p53 / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18335551.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


66. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):217-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Matriptase, a type II transmembrane serine protease is involved in angiogenesis, degradation of extracellular matrix, and in the progression of some epithelial cancers.
  • METHODS: The expression patterns of matriptase and HAI-1 were determined in primary cultures of normal human prostate epithelial (NHPE) cells, human CaP cells LNCaP, DU-145, CWR22Rnu1, and PC-3, and in tissue samples of 172 patients with normal prostate, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma of different tumor grades.
  • A progressive increase in the protein levels of matriptase was observed with increasing tumor grade in CaP specimens as compared with normal and BPH tissue specimens.
  • Tissue samples of normal prostate exhibited a high constitutive protein level of HAI-1 compared with BPH and low-grade cancer with a progressive loss with increasing tumor grade.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Staging / methods. Prostatic Neoplasms / pathology. Serine Endopeptidases / metabolism
  • [MeSH-minor] Disease Progression. Epithelial Cells / metabolism. Humans. Male. Proteinase Inhibitory Proteins, Secretory. RNA, Messenger / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492908.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Proteinase Inhibitory Proteins, Secretory; 0 / RNA, Messenger; 0 / SPINT1 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase
  •  go-up   go-down


67. Papantoniou V, Koutsikos J, Sotiropoulou M, Feida E, Tsiouris S: Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography. Gynecol Oncol; 2005 Jun;97(3):964-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography.
  • BACKGROUND: Breast fibromatosis is a rare, benign, recurring, locally destructive entity.
  • CASE: A 35-year-old woman underwent right-sided lumpectomy, revealing fibromatosis with epithelial hyperplasia.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fibromatosis, Aggressive / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Technetium. Technetium Tc 99m Dimercaptosuccinic Acid

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896828.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 7440-26-8 / Technetium
  •  go-up   go-down


68. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK: Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res; 2008 May;6(5):695-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition.
  • In the current study, we investigated the role of the TGF-beta/Smad3 pathway in ovarian cancer metastasis by regulation of an epithelial-to-mesenchymal transition.
  • When cancer cells were cultured on plastic, TGF-beta1, TGF-beta2, and TGF-beta3 induced pro-matrix metalloproteinase (MMP) secretion, loss of cell-cell junctions, down-regulation of E-cadherin, up-regulation of N-cadherin, and acquisition of a fibroblastoid phenotype, consistent with an epithelial-to-mesenchymal transition.
  • Analysis of Smad3 nuclear expression in microarrays of serous benign tumors, borderline tumors, and cystadenocarcinoma revealed that Smad3 expression could be used to distinguish benign and borderline tumors from carcinoma (P = 0.006).


69. Catalano O, De Lutio di Castelguidone E, Nunziata A, De Rosa V, Siani A: Gastrointestinal stromal tumours: Pictorial review. Radiol Med; 2005 Nov-Dec;110(5-6):484-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumours: Pictorial review.
  • Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the alimentary tract.
  • GISTs are immunohistochemically identified by the expression of the c-kit protein, which is not detected in other mesenchymal tumours.
  • Owing to the frequent exophytic growth of these lesions, differentiation of these tumours from nondigestive lesions of different nature is a common diagnostic problem.
  • Imaging findings usually allow differentiation from gastrointestinal epithelial tumours but not from non-epithelial tumours, for which histological confirmation is necessary, in part to verify potential response to therapy.
  • Smaller lesions, which are usually benign, tend to be well-defined, relatively homogeneous, and with intraluminal growth.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / radiography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437034.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 19
  •  go-up   go-down


70. Tok EC, Ertunc D, Tataroglu C, Yazici G, Kanat H, Dilek S: Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in low-risk women. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):501-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in low-risk women.
  • Possible precursor lesions for epithelial ovarian cancer (EOC) have been defined in the ovaries of women with contralateral EOC, with breast cancer susceptibility gene (BRCA)-1 mutations, or with positive family history.
  • The study group consisted of 184 women who were operated for benign gynecological conditions.
  • Oophorectomy specimens were examined for presence of epithelial inclusion cysts (EIC), cortical invaginations (CI), stromal hyperplasia (SHPP), epithelial pseudostratification (EPS), and surface papillomatosis (SP).
  • [MeSH-major] Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Contraceptives, Oral. Female. Humans. Menopause. Middle Aged. Neoplasm Invasiveness. Ovariectomy. Phenotype. Precancerous Conditions / pathology. Reproduction / physiology. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681718.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


71. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


72. Pitman MB, Genevay M, Yaeger K, Chebib I, Turner BG, Mino-Kenudson M, Brugge WR: High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than "positive" cytology. Cancer Cytopathol; 2010 Dec 25;118(6):434-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than "positive" cytology.
  • In the current study, the authors hypothesized that a cytological threshold of high-grade atypical epithelial cells (AEC) is a more accurate predictor of malignancy.
  • Cytology slides were blindly reviewed and cells were classified as benign, AEC, or malignant.
  • On histology, neoplasms were grouped as benign (low-grade and moderate dysplasia) and malignant (high-grade dysplasia/carcinoma in situ and invasive carcinoma).
  • RESULTS: There were 92 patients with an intraductal papillary mucinous neoplasm (IPMN) and 20 with a mucinous cystic neoplasm; 39 were malignant and 73 were benign (42 with low-grade dysplasia and 31 with moderate dysplasia).
  • Nine of 73 (12%) benign cysts were identified with AEC, 4 of which had moderate dysplasia.
  • AEC had a positive predictive value of 87% for the detection of a mucinous cyst with moderate dysplasia or worse.
  • [MeSH-major] Epithelial Cells / pathology. Pancreatic Cyst / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20931638.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Angiero F, Sozzi D, Seramondi R, Valente MG: Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features. Anticancer Res; 2009 Nov;29(11):4703-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features.
  • AIMS: Epithelial-myoepithelial carcinoma (EMC) is a rare malignant salivary gland neoplasm that most commonly occurs in the parotid gland, but can also arise in the minor salivary glands.
  • Three cases are reported of epithelial-myoepithelial carcinoma of the minor salivary glands, with the goal of better defining this entity.
  • All parts of each tumor were surrounded by a myoepithelial cell rim and there was evidence of invasion.
  • RESULTS: Immunohistochemical analysis showed the tumor cells to be weakly positive for S100, cytokeratin (CK) CK5/6, CK7, CKAE-1/AE-3 and strongly positive for epithelial membrane antigen (EMA) and p63; they were focally positive for calponin and acute lymphoblastic leukemia antigen (CD10).
  • The tumor cells were negative for vimentin, alpha-smooth muscle actin (SMA) (except one case), glial fibrillar acid protein (GFAP) and MIB1.
  • The tumors were resected completely with wide margins and no recurrence or metastasis had occurred from 6 to 15 months after surgery.
  • CONCLUSION: Three cases of minor salivary gland tumors are described and the differential diagnosis underlined in relation to benign myoepithelioma.
  • The characteristic morphological and immunohistochemical features aided diagnosis of these biphasic tumors.
  • [MeSH-minor] Aged. Aged, 80 and over. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratins / biosynthesis. Male. Middle Aged


74. Gos M, Miłoszewska J, Przybyszewska M: [Epithelial-mesenchymal transition in cancer progression]. Postepy Biochem; 2009;55(2):121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial-mesenchymal transition in cancer progression].
  • According to recently published data, the epithelial-mesenchymal transition--a process important for embryonic development, may be involved in many pathological processes such as wound healing, tissue fibrosis or cancer progression.
  • During cancer progression, the EMT process is necessary to the conversion of benign tumor to aggressive and highly invasive cancer.
  • The loss of adhesion is accompanied by molecular and morphologic changes in cancer cells that are essential for the phenotypic change from epithelial to mesenchymal one, and the acquirement of higher migration and invasion potential.
  • During the colonization of distant sites, a reverse process mesenchymal-epithelial transition (MET) takes place and metastatic cancer cells again acquire the epithelial phenotype.
  • It has been suggested that also cells within tumor microenvironment e.g. cancer associated fibroblasts (CAF) are generated in part from normal epithelial cells in EMT process.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology. Mesoderm / pathology. Neoplasms / pathology. Neoplasms / physiopathology
  • [MeSH-minor] Animals. Anoikis. Disease Progression. Humans. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824467.001).
  • [ISSN] 0032-5422
  • [Journal-full-title] Postepy biochemii
  • [ISO-abbreviation] Postepy Biochem.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 73
  •  go-up   go-down


75. Ji Y, Zhang P, Lu Y, Ma D: Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication. J Huazhong Univ Sci Technolog Med Sci; 2006;26(3):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MTA2 gene in ovarian epithelial cancer and its clinical implication.
  • In order to investigate the roles of MTA2 in the pathogenesis of ovarian epithelial cancer, the expression of MTA2 in 4 ovarian cell lines were detected by semi-quantitative RT-PCR and Western-blot assays.
  • MTA2 expression in normal, borderline, benign and malignant epithelial ovarian tissues was immunohistochemically examined.
  • The expression of MTA2 mRNA and protein was detected in all of 4 cell lines of ovarian epithelial cancer.
  • In borderline and malignant ovarian tissues tested, MTA2 staining was dramatically stronger than in normal and benign tissues (P < 0.01).
  • The expression levels in malignant ovarian tissues were significantly higher than that in borderline epithelial ovarian tissues (P < 0.01).
  • It was concluded that the high expression of MTA2 was associated with more aggressive behaviors of epithelial ovarian cancer.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Cell Line, Tumor. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Nov 16;408(6810):377-81 [11099047.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):30-7 [14613024.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1924-35 [10444591.001]
  • [Cites] J Hum Genet. 1999;44(1):52-6 [9929979.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Aug;25(4):434-7 [12974090.001]
  • (PMID = 16961294.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Repressor Proteins; EC 3.5.1.- / MTA2 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


76. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC Jr: Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol; 2007 Sep;106(3):490-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mesothelin was assayed in the serum and in the urine from 28 patients with early stage (I/II) invasive epithelial ovarian cancers, 111 with advanced stage (III/IV) invasive disease and 19 with tumors of low malignant potential.
  • Marker values have been compared to those in healthy controls and 115 patients with benign pelvic masses.
  • [MeSH-major] Biomarkers, Tumor / urine. Chorionic Gonadotropin, beta Subunit, Human / urine. Membrane Glycoproteins / urine. Ovarian Neoplasms / urine. Peptide Fragments / urine
  • [MeSH-minor] CA-125 Antigen / blood. Female. GPI-Linked Proteins. Glomerular Filtration Rate. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Biochemistry. 2003 May 6;42(17):4864-73 [12718527.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] BMC Cancer. 2004 May 12;4:19 [15140265.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Yale J Biol Med. 1989 Jul-Aug;62(4):367-78 [2596125.001]
  • [Cites] Fetal Diagn Ther. 1997 Nov-Dec;12(6):336-9 [9475362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):684-94 [15721412.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):432-41 [16428483.001]
  • (PMID = 17532030.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Peptide Fragments; 0 / mesothelin; 0 / urinary gonadotropin fragment
  • [Other-IDs] NLM/ NIHMS30261; NLM/ PMC3374586
  •  go-up   go-down


77. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


78. Dunham CP, Curry B, Hamilton M: Malignant transformation of an intraaxial-supratentorial neurenteric cyst - case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):460-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurenteric cysts are "rare benign mass forming developmental abnormalities" that usually affect young adults.
  • Neurenteric cysts are lined by simple-to-pseudostratified respiratory/gastrointestinal-like epithelium; as such, these lesions closely resemble colloid and Rathke's cleft cysts.
  • Malignant transformation of the epithelial component of neurenteric cysts is decidedly rare.
  • Areas of direct transition between typical benign neurenteric cyst epithelia and malignant epithelia (i.e., carcinoma in situ), highlighted by an abrupt change in the Ki-67 proliferative index, were identified, and supported the primary nature of this brain neoplasm.

  • MedlinePlus Health Information. consumer health - Neural Tube Defects.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919821.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


79. Depondt J, Shabana el-H, Walker F, Pibouin L, Lezot F, Berdal A: Nasal inverted papilloma expresses the muscle segment homeobox gene Msx2: possible prognostic implications. Hum Pathol; 2008 Mar;39(3):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal inverted papilloma is a rare benign tumor of epithelial origin with aggressive evolution, bone destruction, recurrence, and malignant transformation.
  • The protein expression level was directly and significantly associated with tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Homeodomain Proteins / biosynthesis. Nose Neoplasms / genetics. Nose Neoplasms / metabolism. Papilloma, Inverted / genetics. Papilloma, Inverted / metabolism
  • [MeSH-minor] Acid Phosphatase / metabolism. Adult. Aged. Female. Gene Expression. Genes, Homeobox / physiology. Humans. Immunohistochemistry. Isoenzymes / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. RANK Ligand / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187185.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / MSX2 protein; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


80. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA: Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res; 2006 Nov-Dec;26(6C):4721-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
  • The aim of this study was to determine the relationship between mesothelin and clinical pathological characteristics and whether mesothelin can be used as a biomarker for the detection and prognosis of epithelial ovarian carcinoma, or not.
  • PATIENTS AND METHODS: Pre-operative mesothelin and CA125 levels from normal populations, patients with benign ovarian tumors and patients with ovarian carcinomas were measured.
  • RESULTS: Mesothelin levels were higher in cancer patients than in those with benign ovarian tumors or in normal populations.
  • CONCLUSION: Mesothelin might be a new tumor marker for the differential diagnosis of epithelial ovarian carcinoma and a prognostic factorfor the outcome of epithelial ovarian carcinoma patients.
  • [MeSH-minor] Adult. CA-125 Antigen / blood. Cystadenoma / blood. Cystadenoma / pathology. Epithelial Cells / pathology. Female. GPI-Linked Proteins. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214332.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


81. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


82. Glazebrook KN, Morton MJ, Reynolds C: Carcinoma of the breast mimicking an areolar dermal lesion. J Ultrasound Med; 2007 Aug;26(8):1083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This report describes the sonographic features of 2 patients with invasive carcinoma of the breast that sonographically mimicked benign epithelial cysts of the areola.
  • CONCLUSIONS: Lesions in the subcutaneous tissue superficial to the anterior pectoral fascia are extraparenchymal in origin and typically are benign.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Skin Diseases / pathology. Skin Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646371.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


84. Muenscher A, Diegel T, Jaehne M, Ussmüller J, Koops S, Sanchez-Hanke M: Benign and malignant salivary gland diseases in children A retrospective study of 549 cases from the Salivary Gland Registry, Hamburg. Auris Nasus Larynx; 2009 Jun;36(3):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant salivary gland diseases in children A retrospective study of 549 cases from the Salivary Gland Registry, Hamburg.
  • OBJECTIVE: Tumors of salivary glands in children are rare.
  • Basically all types of salivary gland diseases during the period of childhood are described.
  • The incidences of salivary gland tumors in children (0-14 years) differ completely from those in adults.
  • As a reference centre for salivary gland diseases some material was sent by other institutions.
  • RESULTS: This study will give a detailed survey of salivary gland diseases and tumors in children up to the age of 14 which have undergone surgical therapy/biopsy.
  • We present the general distribution of the different tumors/diseases, the distribution in certain age groups and the various locations.
  • Comparing the distribution of malignant tumors with other studies, the epithelial-myoepithelial carcinomas followed by salivary duct carcinomas represent the largest group in childhood.
  • CONCLUSIONS: The study shows that comparing to adulthood different tumors play an important role in adolescence.
  • The distribution of tumors in childhood may help in diagnostic.
  • Further many salivary gland diseases in childhood underwent surgery/biopsy although this is not supposed to be the proper treatment.
  • [MeSH-minor] Adolescent. Biopsy. Catchment Area (Health). Child. Child, Preschool. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18809268.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Mentzel T, Schärer L, Kazakov DV, Michal M: Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol; 2007 Oct;29(5):443-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatofibrosarcoma protuberans (DFSP) represents a locally aggressive mesenchymal neoplasm of skin and subcutis with characteristic clinicopathologic, immunohistochemical, and molecular findings.
  • In addition to typical cases, morphologic variants such as pigmented, fibrosarcomatous, myofibroblastic, and granular cell DFSP have been described.
  • Tumor size ranged from 1.5 to 12 cm.
  • Histologically, a nodular growth with peripheral diffuse infiltration, as well as a diffusely infiltrating growth of relatively uniform spindled and stellated tumor cells containing slightly enlarged nuclei, was noted.
  • Three cases were entirely myxoid, and in five cases more than 80% of the tumor area showed myxoid stromal changes.
  • Scattered enlarged tumor cells were seen in two cases.
  • Immunohistochemically, tumor cells in all cases stained positively for CD34, and in one case each a focal expression of alpha-smooth muscle actin and epithelial membrane antigen (EMA) was noted.
  • In conclusion, myxoid DFSP represents a very rare morphologic variant with characteristic changes that has to be distinguished from benign and malignant myxoid mesenchymal neoplasms as superficial angiomyxoma, superficial acral fibromyxoma, myxoid solitary fibrous tumor, myxoid perineurioma, low-grade myxofibrosarcoma, low-grade fibromyxoid sarcoma, myxoid liposarcoma, and myxoid synovial sarcoma.

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890911.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Collagen Type I; 0 / Mucin-1; 0 / Proto-Oncogene Proteins c-sis; 0 / collagen type I, alpha 1 chain
  •  go-up   go-down


86. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G: Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res; 2008 Feb 1;14(3):758-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, quantitative expression features of PSA/HK3 mRNA in prostate tumor cells may serve as a prognostic indicator of disease progression.
  • EXPERIMENTAL DESIGN: Paired benign and malignant epithelial cells (242 specimens) were obtained from laser capture microdissection of frozen OCT-embedded tissue sections prepared from radical prostatectomy specimens of 121 patients.
  • Quantitative expression of PSA/HK3 mRNA in the matched malignant and benign cells was analyzed by real-time reverse transcription-PCR.
  • RESULTS: CaP cells express significantly lower PSA/HK3 mRNA levels than matched benign cells (P = 0.0133).
  • [MeSH-minor] Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Male. Prognosis. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction


87. Driemel O, Berndt A, Hartmann A, Mueller-Richter UD, Bauer R, Reichert TE, Kosmehl H: [Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas]. Mund Kiefer Gesichtschir; 2006 Jul;10(4):239-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A clinico-pathologic study of typical symptoms of intra- and extraoral angiosarcomas and clinical course under therapy is presented as well as an analysis of the immunohistochemical differential diagnosis of the tumour specific formed spaces.
  • RESULTS: While the benign appearance of the lesions resulted primarily in wrong diagnoses the histopathologic examination of the biopsies revealed the characteristic pattern of angiosarcomas.
  • Wide surgical excision, radiotherapy and/or antiangiogenic chemotherapy could not prevent tumour progression and death within two and a half years after primary diagnosis.
  • The tumour associated structural defect of vascular lamina with partial loss of pericytes/vascular smooth muscle cells was identified immunohistochemically by alpha-smooth-muscle-actin and for the first time by tenascin-C.
  • ) The variable presentation and the benign appearance of oral and perioral angiosarcomas may often delay diagnosis.
  • ) Cytoceratin and laminin-5-positivity as typical epithelial antigens don't exclude angiosarcoma.
  • [MeSH-major] Alveolar Process. Biomarkers, Tumor / analysis. Cheek. Hemangiosarcoma / pathology. Mandibular Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1996 Dec;429(6):311-22 [8982375.001]
  • [Cites] In Vitro Cell Dev Biol. 1991 Aug;27A(8):651-9 [1717427.001]
  • [Cites] Cutis. 2005 Nov;76(5):313-7 [16422466.001]
  • [Cites] Curr Oncol Rep. 2002 Nov;4(6):515-9 [12354365.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2005 May;19(3):357-9 [15857466.001]
  • [Cites] Eur J Dermatol. 2000 Jun;10(4):300-2 [10846259.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Plast Reconstr Surg. 2006 Feb;117(2):687-8 [16462373.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):683-97 [9630175.001]
  • [Cites] Clin Orthop Relat Res. 1995 Apr;(313):81-91 [7543836.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4384-92 [12933583.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Mar;8(2):118-22 [15045535.001]
  • [Cites] Ultrastruct Pathol. 1997 Nov-Dec;21(6):537-44 [9355236.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):523-33 [15087672.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Sep;17(5):594-5 [12941106.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):361-6 [15948172.001]
  • [Cites] FASEB J. 2005 Feb;19(2):270-1 [15579670.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):48-57 [12502927.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2251-6 [14601096.001]
  • (PMID = 16788797.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Kurman RJ, Shih IeM: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol; 2010 Mar;34(3):433-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
  • Efforts at early detection and new therapeutic approaches to reduce mortality have been largely unsuccessful, because the origin and pathogenesis of epithelial ovarian cancer are poorly understood.
  • This has led to the proposal that ovarian cancer develops de novo.
  • Studies have shown that epithelial ovarian cancer is not a single disease but is composed of a diverse group of tumors that can be classified based on distinctive morphologic and molecular genetic features.
  • One group of tumors, designated type I, is composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional (Brenner) carcinomas.
  • These tumors generally behave in an indolent fashion, are confined to the ovary at presentation and, as a group, are relatively genetically stable.
  • Moreover, the carcinomas exhibit a shared lineage with the corresponding benign cystic neoplasm, often through an intermediate (borderline tumor) step, supporting the morphologic continuum of tumor progression.
  • In contrast, another group of tumors, designated type II, is highly aggressive, evolves rapidly and almost always presents in advanced stage.
  • Type II tumors include conventional high-grade serous carcinoma, undifferentiated carcinoma, and malignant mixed mesodermal tumors (carcinosarcoma).
  • They displayTP53 mutations in over 80% of cases and rarely harbor the mutations that are found in the type I tumors.
  • Recent studies have also provided cogent evidence that what have been traditionally thought to be primary ovarian tumors actually originate in other pelvic organs and involve the ovary secondarily.
  • Thus, it has been proposed that serous tumors arise from the implantation of epithelium (benign or malignant) from the fallopian tube.
  • Endometrioid and clear cell tumors have been associated with endometriosis that is regarded as the precursor of these tumors.
  • Finally, preliminary data suggest that mucinous and transitional (Brenner) tumors arise from transitional-type epithelial nests at the tubal-mesothelial junction by a process of metaplasia.
  • Appreciation of these new concepts will allow for a more rationale approach to screening, treatment, and prevention that potentially can have a significant impact on reducing the mortality of this devastating disease.


89. Sato K, Ueda Y, Miwa S, Yokogawa A, Ozaki M, Katsuda S: Low-grade malignant soft-tissue perineurioma: interphase fluorescence in situ hybridization. Pathol Int; 2008 Nov;58(11):718-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perineuriomas are usually benign soft-tissue tumors that arise from perineurial cells of the peripheral nerve sheath.
  • This report describes a case of low-grade malignant perineurioma in a 60-year-old man who presented with a growing tumor on the dorsal side of his left wrist.
  • The tumor was surgically excised and showed no adhesion to the surrounding muscle and no continuity with nerves.
  • Histology indicated that the tumor contained hypercellular and hypocellular areas with spindle-shaped cells proliferating in storiform patterns or perivascular whorling.
  • On immunohistochemistry tumor cells were found to be positive for epithelial membrane antigen, glucose transporter protein 1, and claudin-1.
  • Approximately 18.4% of tumor nuclei were labelled for Ki-67.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Nucleus / chemistry. Cell Nucleus / pathology. Chromosome Aberrations. Chromosomes, Human, Pair 13. Claudin-1. DNA, Neoplasm / analysis. Glucose Transporter Type 1 / analysis. Humans. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. Male. Membrane Proteins / analysis. Middle Aged. Mitosis. Mucin-1 / analysis. Treatment Outcome. Wrist / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844938.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / DNA, Neoplasm; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Mucin-1
  •  go-up   go-down


90. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


91. Gümgüm S, Hoşgören B: Clinical and radiologic behaviour of ameloblastoma in 4 cases. J Can Dent Assoc; 2005 Jul-Aug;71(7):481-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a benign but locally aggressive epithelial odontogenic neoplasm.
  • It represents 1% of all tumours of the jaw bone.
  • We describe the clinical and radiologic behaviour of ameloblastoma and discuss treatment protocols and the possibility of conservative management of this tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026635.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


92. Lin TY, Zhang AY, Bayer-Garner IB, Krell JM, Acker SM: Epithelial sheath neuroma: a case report and discussion of the literature. Am J Dermatopathol; 2006 Jun;28(3):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial sheath neuroma: a case report and discussion of the literature.
  • Here, a case of a rare epithelial sheath neuroma (ESN) is reported.
  • ESN is characterized by enlarged nerve fibers ensheathed by a sometimes keratinized squamous epithelium located in the superficial dermis where large nerves are not normally found.
  • It is believed to be a benign neoplasm and simple excision is curative.
  • [MeSH-minor] Dermis / pathology. Epithelium / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778489.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


93. Gaissert HA, Mark EJ: Tracheobronchial gland tumors. Cancer Control; 2006 Oct;13(4):286-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracheobronchial gland tumors.
  • BACKGROUND: Tracheal tumors are uncommon, making up only 0.2% of all respiratory malignancies in the United States.
  • Bronchial gland tumors demonstrate oncologic diversity and include benign, low-grade, and high-grade malignant tumors.
  • METHODS: We reviewed the present knowledge of bronchial gland tumors of the trachea, carina, and bronchi, including the epidemiology, presentation, evaluation, tumor types, and treatment options.
  • RESULTS: The malignant bronchial gland tumors, adenoid cystic carcinoma and mucoepidermoid carcinoma, are far more common than benign mucinous cystadenoma or pleomorphic adenoma.
  • Complete resection of localized tumors has excellent long-term results in symptomatic benign tumors.
  • The disease-free survival after resection of malignant tumors is limited by distant metastasis and regional disease, while local recurrence is uncommon.
  • CONCLUSIONS: Expanding knowledge of diagnostic evaluation and surgical therapy can improve the long-term survival of patients with tracheobronchial gland tumors.
  • [MeSH-major] Bronchial Neoplasms. Neoplasms, Glandular and Epithelial. Tracheal Neoplasms
  • [MeSH-minor] Clinical Trials as Topic. Humans. Neoplasm Staging. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy. Thoracic Surgical Procedures. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075566.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


94. Van Holsbeke C, Van Belle V, Leone FP, Guerriero S, Paladini D, Melis GB, Greggi S, Fischerova D, De Jonge E, Neven P, Bourne T, Valentin L, Van Huffel S, Timmerman D: Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound Obstet Gynecol; 2010 Jul;36(1):81-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology.
  • OBJECTIVE: To determine the sensitivity and specificity of the 'ovarian crescent sign' (OCS)-a rim of normal ovarian tissue seen adjacent to an ipsilateral adnexal mass-as a sonographic feature to discriminate between benign and malignant adnexal masses.
  • METHODS: The patients included were a subgroup of patients participating in the International Ovarian Tumor Analysis (IOTA) Phase 2 study, which is an international multicenter study.
  • The ability of the OCS to discriminate between borderline or invasively malignant vs. benign adnexal masses, as well as between invasively malignant vs. other (benign and borderline) tumors, was determined and compared with the performance of subjective evaluation of ultrasound findings by the ultrasound examiner.
  • RESULTS: The OCS was evaluated in 1377 adnexal masses from 12 centers, 938 (68%) masses being benign, 86 (6%) borderline, 305 (22%) primary invasive and 48 (3%) metastases.
  • The OCS was present in 398 (42%) of 938 benign masses, in 14 (16%) of 86 borderline tumors, in 18 (6%) of 305 primary invasive tumors (one malignant struma ovarii, one uterine clear cell adenocarcinoma and 16 epithelial carcinomas, i.e. four Stage I and 12 Stage II-IV) and in two (4%) of 48 ovarian metastases.
  • For discrimination between invasive vs. benign or borderline tumors, the sensitivity for absent OCS was 94%, the specificity was 40%, the LR+ was 1.58 and the LR- was 0.14.
  • However it is a poor discriminator between benign and malignant adnexal masses.
  • [MeSH-minor] Adnexal Diseases / ultrasonography. Diagnosis, Differential. Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20217895.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


95. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML: Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol; 2009 Jan;112(1):185-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
  • OBJECTIVES: The invasive growth of circulating tumor cells (CTCs) propagates cancer metastasis.
  • METHODS: Peripheral blood samples from 71 patients undergoing evaluation for ovarian malignancy were assessed for the presence of invasive CTCs using a cell invasion assay that enriches and identifies tumor cells with a cell adhesion matrix (CAM).
  • Invasive CTCs were identified as cells exhibiting CAM invasion (CAM+) and expressing standard epithelial markers (Epi+).
  • RESULTS: 43 (60.6%) patients had detectable CTCs: 0/5 benign patients, 1/10 (10%) early stage, 39/52 (73.1%) late stage and 3/4 (75%) unstaged patients (p-value <0.001).
  • CTC counts ranged from 0-149 CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts (41.3 CTCs/ml) than stage I/II patients (6.0 CTCs/ml) and benign patients (0 CTCs/ml, p-value=0.001).
  • Tumor grade and tumor histology did not influence CTC detection.
  • CONCLUSIONS: Invasive CTCs can be detected in a majority of epithelial ovarian cancer patients and may predict shorter disease-free survival.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Feb 1;94(3):707-12 [11857303.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):389-94 [14599871.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3584-92 [6744281.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):442-5 [2227559.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):942-7 [16889820.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):180-204 [17314005.001]
  • [Cites] Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1047-55 [17433065.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):171-81 [18058027.001]
  • [Cites] Nat Med. 2000 Jan;6(1):100-2 [10613833.001]
  • [Cites] Mol Diagn. 2000 Mar;5(1):33-8 [10837087.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):785-92 [10997804.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):368-75 [11208828.001]
  • (PMID = 18954898.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103467-01; United States / NIBIB NIH HHS / EB / EB002065-21; United States / NCI NIH HHS / CA / CA108247-02; United States / NCI NIH HHS / CA / R42 CA108247-04; United States / NIBIB NIH HHS / EB / R01 EB002065-21; United States / NCRR NIH HHS / RR / RR010710-070061; United States / NCI NIH HHS / CA / CA108247-03; United States / NCI NIH HHS / CA / R42 CA108247-03; United States / NCI NIH HHS / CA / R42 CA108247-01; United States / NCI NIH HHS / CA / R41 CA103467-01; United States / NCI NIH HHS / CA / CA108247-04; United States / NCI NIH HHS / CA / CA039077-23; United States / NCI NIH HHS / CA / R42 CA108247-02; United States / NCI NIH HHS / CA / R01 CA039077-23; United States / NCI NIH HHS / CA / CA108247-01; United States / NCRR NIH HHS / RR / M01 RR010710-070061
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ NIHMS69436; NLM/ PMC2606929
  •  go-up   go-down


96. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K: KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol; 2005 Feb;29(2):188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
  • The purposes of this study were 1) to assess KOC mRNA expression in pancreatic carcinoma, 2) to determine the pattern of KOC immunoexpression among benign, borderline, and malignant pancreatic epithelial lesions, and 3) to evaluate the utility of the KOC antibody in distinguishing between these entities. mRNA was isolated from fresh pancreatic tissues (19 carcinomas, 2 normal pancreas, 1 chronic pancreatitis) and amplified using standard RT-PCR techniques.
  • Fifteen of 19 (79%) carcinomas overexpressed KOC mRNA relative to non-neoplastic tissue samples and expression increased progressively with tumor stage: the mean copy number of KOC mRNA transcripts was 1.5, 11.1, 31, and 28 for stage I, II, III, and IV carcinomas, respectively, compared with 0.9 and 1 for normal pancreatic tissue and chronic pancreatitis, respectively.
  • KOC staining was present in 37 of 38 (97%) carcinomas: the staining reaction was moderate or strong in 36 of 38 (94%) and present in >50% of the tumor cells in 35 of 38 (92%) cases.
  • Severe dysplasia of the ductal epithelium, present in 19 foci of intraductal papillary mucinous carcinoma, mucinous cystadenocarcinoma, and grade 3 pancreatic intraepithelial neoplasia (PanIN3) showed strong or moderate staining in 15 (79%) cases, whereas foci of mild and moderate dysplasia (intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms with adenoma and/or moderate dysplasia, PanIN1, and PanIN2) were uniformly negative for this marker in 25 and 22 cases, respectively.
  • In the normal pancreas, weak background staining of acini was present in 12 of 50 (24%) cases but was easily distinguishable from the type of staining identified in neoplastic epithelium, and benign ducts and ductules were negative in all cases.
  • We conclude that KOC is a sensitive and specific marker for carcinomas and high-grade dysplastic lesions of the pancreatic ductal epithelium.
  • [MeSH-major] Biomarkers, Tumor / analysis. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Animals. Humans. Immunohistochemistry. Neoplasm Proteins. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644775.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


97. Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM: MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer; 2010;10:497
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
  • MAL2 binds tumor protein D52 (TPD52), which is frequently overexpressed in ovarian carcinoma, but the clinical significance of MAL2 and TPD52 overexpression was unknown.
  • METHODS: Immunohistochemical analyses of MAL2 and TPD52 expression were performed using tissue microarray sections including benign, borderline and malignant epithelial ovarian tumours.
  • RESULTS: MAL2 and TPD52 were significantly overexpressed in high-grade serous carcinomas compared with serous borderline tumours.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / metabolism. Proteolipids / metabolism. Vesicular Transport Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cohort Studies. Female. Humans. Immunoenzyme Techniques. Middle Aged. Myelin and Lymphocyte-Associated Proteolipid Proteins. Neoplasm Staging. Neoplasm, Residual / metabolism. Neoplasm, Residual / pathology. Prognosis. Survival Rate. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1115-21 [15555543.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1794-801 [15688027.001]
  • [Cites] Mol Cancer. 2005;4:26 [16042759.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1049-54 [15986428.001]
  • [Cites] Nat Clin Pract Oncol. 2005 May;2(5):246-54 [16264960.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84 [16361540.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):306-16 [16321566.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):421-30 [16518402.001]
  • [Cites] BMC Cancer. 2006;6:92 [16608533.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):6937-45 [17145811.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1511-7 [17192896.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):133-44 [17314271.001]
  • [Cites] PLoS One. 2007;2(3):e323 [17389914.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4731-9 [17699850.001]
  • [Cites] J Pathol. 2007 Sep;213(1):46-55 [17668415.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8906-13 [17875733.001]
  • [Cites] BMC Cancer. 2007;7:226 [18088415.001]
  • [Cites] BMC Syst Biol. 2008;2:2 [18173842.001]
  • [Cites] Br J Cancer. 2008 Jun 17;98(12):1999-2005 [18506145.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5050-60 [18698023.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Mol Cancer Res. 2008 Oct;6(10):1544-53 [18922970.001]
  • [Cites] Crit Rev Oncog. 2008;14(1):33-55 [19105569.001]
  • [Cites] BMC Cell Biol. 2009;10:7 [19175940.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2269-80 [19293255.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):3795-801 [19336569.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] J Proteome Res. 2009 Mar;8(3):1452-63 [19159301.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):281-94 [18642118.001]
  • [Cites] Fertil Steril. 2010 Sep;94(4):1212-7 [19643405.001]
  • [Cites] Oncology. 2000 Jun;59(1):50-6 [10895067.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28866-72 [11384973.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Genomics. 2001 Aug;76(1-3):81-8 [11549320.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):37-44 [12370246.001]
  • [Cites] Trends Biochem Sci. 2002 Dec;27(12):599-601 [12468223.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8861-8 [14695203.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1085-94 [15173114.001]
  • (PMID = 20846453.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAL2 protein, human; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / TPD52 protein, human; 0 / Vesicular Transport Proteins
  • [Other-IDs] NLM/ PMC2949808
  •  go-up   go-down


98. Williams SB, Ellis GL, Warnock GR: Sialoblastoma: a clinicopathologic and immunohistochemical study of 7 cases. Ann Diagn Pathol; 2006 Dec;10(6):320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sialoblastoma is a rare congenital or perinatal salivary tumor that varies in histologic features and biologic potential.
  • These tumors occurred in 4 males and 3 females with ages ranging from prenatal to 6 months at the time of discovery.
  • (1) a favorable pattern had semiencapsulation of cytologically benign basaloid tumor cells with intervening stroma; and (2) an unfavorable histology of anaplastic basaloid tumor cells, minimal stroma, and broad pushing to infiltrative periphery.
  • Four and three tumors had favorable and unfavorable growth patterns, respectively.
  • All 3 tumors with unfavorable histology recurred.
  • Tumor cells in 3 cases were immunohistochemically reactive for keratin, S-100, smooth muscle actin, and calponin to varying degrees.
  • All 3 tumors were reactive for p63. alpha-Fetoprotein was expressed in 2 unfavorable tumors.
  • Ki67 was expressed at 3% in a favorable tumor and 40% and 80% in the 2 unfavorable lesions.
  • [MeSH-major] Mixed Tumor, Malignant / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Ki-67 Antigen / analysis. Male. Neoplasm Recurrence, Local. Treatment Outcome. alpha-Fetoproteins / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126248.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


99. Akhtar K, Khan N, Zaheer S, Sherwani R, Hasan A: Pindborg tumor in an adolescent. Oman Med J; 2010 Jan;25(1):47-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pindborg tumor in an adolescent.
  • Calcifying epithelial odontogenic tumor (Pindborg tumor), is a rare benign odontogenic neoplasm representing about 0.4-3% of all odontogenic tumors.
  • This tumor more frequently affects adults in the age range of 20-60 years, with a peak incidence in the 5th decade of life.
  • Calcifying epithelial odontogenic tumour has a much lower recurrence rate than ameloblastoma and malignant transformation, and metastasis is rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22125699.001).
  • [ISSN] 2070-5204
  • [Journal-full-title] Oman medical journal
  • [ISO-abbreviation] Oman Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3215391
  •  go-up   go-down


100. Bhalla RK, Wright ED: Predicting the site of attachment of sinonasal inverted papilloma. Rhinology; 2009 Dec;47(4):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STATEMENT OF PROBLEM: Sinonasal inverted papilloma is a benign, epithelial neoplasm, which has a propensity for malignant transformation and recurrence.
  • The evolution of endoscopic trans-nasal surgery has facilitated less destructive and, more functionally and cosmetically acceptable approaches to this tumour.
  • Precise surgery is enhanced by pre-operative localisation of the site of tumour attachment.
  • Intra-operatively, the actual site of tumour attachment was established.
  • A correlation between the predicted and actual site of tumour attachment was calculated.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936356.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement